



**HAL**  
open science

## **ARID1A loss in adult hepatocytes activates $\beta$ -catenin-mediated erythropoietin transcription**

Rozenn Riou, Meriem Ladli, Sabine Gerbal-Chaloin, Pascale Bossard,  
Angélique Gougelet, Cécile Godard, Robin Loesch, Isabelle Lagoutte, F.  
Lager, Julien Caldéraro, et al.

### ► To cite this version:

Rozenn Riou, Meriem Ladli, Sabine Gerbal-Chaloin, Pascale Bossard, Angélique Gougelet, et al..  
ARID1A loss in adult hepatocytes activates  $\beta$ -catenin-mediated erythropoietin transcription. *eLife*,  
2020, 9, pp.e53550. 10.7554/elife.53550 . hal-03010546

**HAL Id: hal-03010546**

**<https://hal.science/hal-03010546>**

Submitted on 5 Jan 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# ARID1A loss in adult hepatocytes activates $\beta$ -catenin-mediated erythropoietin transcription

Rozenn Riou<sup>1,2,3</sup>, Meriem Ladli<sup>3</sup>, Sabine Gerbal-Chaloin<sup>4</sup>, Pascale Bossard<sup>2,3</sup>, Angélique Gougelet<sup>1,2,3</sup>, Cécile Godard<sup>1,2,3</sup>, Robin Loesch<sup>1,2,3</sup>, Isabelle Lagoutte<sup>3,5</sup>, Franck Lager<sup>3,5</sup>, Julien Calderaro<sup>6,7</sup>, Alexandre Dos Santos<sup>8</sup>, Zhong Wang<sup>9</sup>, Frédérique Verdier<sup>3</sup>, Sabine Colnot<sup>1,2,3\*</sup>

<sup>1</sup>INSERM, Sorbonne Université, Université de Paris, Centre de Recherche des Cordeliers (CRC), Paris, France; <sup>2</sup>Equipe labellisée Ligue Nationale Contre le Cancer, Paris, France; <sup>3</sup>INSERM, CNRS, Institut COCHIN, Paris, France; <sup>4</sup>INSERM U1183, Université Montpellier, Institute for Regenerative Medicine & Biotherapy (IRMB), Montpellier, France; <sup>5</sup>Plateforme d'Imageries du Vivant de l'Université de Paris, Paris, France; <sup>6</sup>INSERM, Université Paris-Est UPEC, Créteil, France; <sup>7</sup>Department of Pathology, Henri Mondor Hospital, Créteil, France; <sup>8</sup>INSERM, Paul-Brousse University Hospital, Hepatobiliary Centre, Villejuif, France; <sup>9</sup>Department of Cardiac Surgery Cardiovascular Research Center, University of Michigan, Ann Arbor, United States

**Abstract** Erythropoietin (EPO) is a key regulator of erythropoiesis. The embryonic liver is the main site of erythropoietin synthesis, after which the kidney takes over. The adult liver retains the ability to express EPO, and we discovered here new players of this transcription, distinct from the classical hypoxia-inducible factor pathway. In mice, genetically invalidated in hepatocytes for the chromatin remodeler *Arid1a*, and for *Apc*, the major silencer of Wnt pathway, chromatin was more accessible and histone marks turned into active ones at the *Epo* downstream enhancer. Activating  $\beta$ -catenin signaling increased binding of Tcf4/ $\beta$ -catenin complex and upregulated its enhancer function. The loss of *Arid1a* together with  $\beta$ -catenin signaling, resulted in cell-autonomous *EPO* transcription in mouse and human hepatocytes. In mice with *Apc-Arid1a* gene invalidations in single hepatocytes, *Epo* de novo synthesis led to its secretion, to splenic erythropoiesis and to dramatic erythrocytosis. Thus, we identified new hepatic *EPO* regulation mechanism stimulating erythropoiesis.

\*For correspondence: [sabine.colnot@inserm.fr](mailto:sabine.colnot@inserm.fr)

**Competing interests:** The authors declare that no competing interests exist.

**Funding:** See page 25

**Received:** 12 November 2019

**Accepted:** 20 October 2020

**Published:** 21 October 2020

**Reviewing editor:** Irwin Davidson, Institut de Génétique et de Biologie Moléculaire et Cellulaire, France

© Copyright Riou et al. This article is distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.

## Introduction

Chromatin dynamics strongly modulates gene expression, and the liver is a prominent tissue in which chromatin opening is a pre-pattern for cell fate programming (Zaret, 2016). ARID1A, 'AT-rich interacting domain containing protein 1A', is a BAF (BRG1-associated factors) subunit of the highly evolutionarily conserved SWI/SNF chromatin remodeling complexes. These complexes use the energy of ATP hydroxylation to reposition, eject, or exchange nucleosomes and thus modulate DNA accessibility (de la Serna et al., 2006). They are essential for the regulation of gene expression and are involved in several cellular functions, such as differentiation, development, proliferation, DNA repair, and adaptation to the extracellular environment (Kadoch et al., 2016). Recently, mutations in chromatin modifying factors have been identified in several types of cancer (Kadoch et al., 2016).

In the adult mouse liver, *Arid1a* has been shown to play a role in liver regeneration and in tumorigenesis (Sun et al., 2018; Sun et al., 2016). In human hepatocellular carcinoma (HCC), the most common primary liver cancer (Torre et al., 2016), *ARID1A* is the chromatin modifier gene the most frequently inactivated (>13% of HCCs). These mutations are preferentially found in HCC with activating mutations of the *CTNNB1* gene encoding  $\beta$ -catenin, accounting for one third of HCC (Guichard et al., 2012; Rebouissou et al., 2016). This suggested a potential link between Wnt/ $\beta$ -catenin pathway and *ARID1A* for the regulation of hepato-specific gene expression programs involved in liver pathophysiology.

In the adult liver, the Wnt/ $\beta$ -catenin pathway can induce both physiological and oncogenic effects (Cavard et al., 2008; Colnot, 2016; Monga, 2015). Such signaling is restricted to the hepatocytes surrounding the central vein, the so-called pericentral hepatocytes, where it is activated by nearby endothelial Wnt and R-Spondin ligands (Planas-Paz et al., 2016; Benhamouche et al., 2006).  $\beta$ -catenin transcriptionally patterns the liver to ensure its pericentral metabolic functions (Gougelet et al., 2014; Torre et al., 2011). A genetically engineered panlobular activation of the Wnt/ $\beta$ -catenin pathway quickly induced a pericentral-like liver phenotype and hepatomegaly, resulting in mouse death (Benhamouche et al., 2006). Additionally, the focal activation of  $\beta$ -catenin in vivo in single murine hepatocytes is oncogenic, leading to the development of  $\beta$ -catenin-activated liver tumors (Colnot et al., 2004). We used transcriptomic and metabolomic approaches and showed that the genetic program expressed in  $\beta$ -catenin-activated liver is similar to the oncogenic signature found in human HCC harboring activating  $\beta$ -catenin mutations (Gougelet et al., 2014; Gougelet et al., 2019; Senni et al., 2019).


When activated,  $\beta$ -catenin translocates into the nucleus and interacts with its co-factor Tcf4 to bind Wnt-responsive elements (WRE) located in the vicinity of target genes (Gougelet et al., 2014). Chromatin remodeling processes have been shown to unlock chromatin over WREs, allowing  $\beta$ -catenin to dictate specific transcriptomic programs (Mosimann et al., 2009). Given the frequent inactivation of *ARID1A* in *CTNNB1*-mutated liver tumors, our aim was to determine in mice whether and how the loss of the chromatin remodeler *Arid1a* cooperates with  $\beta$ -catenin to impact on mouse liver pathophysiology. We used transgenic murine models in which the main brake of the Wnt/ $\beta$ -catenin pathway, the tumor suppressor *Adenomatous polyposis coli* (*Apc*) (Colnot et al., 2004) and/or *Arid1a* (Gao et al., 2008) are lost in adult hepatocytes. We unexpectedly revealed a novel major function of *ARID1A* and the Wnt/ $\beta$ -catenin pathway in regulating *EPO* expression and adult erythropoiesis.

## Results

### Emergence of peliosis-like regions in the liver of [*Apc-Arid1a*]<sup>ko-focal</sup> mice

We investigated the effects of the loss of the chromatin remodeler *Arid1a* in a context of focal and aberrant  $\beta$ -catenin activation. To do so, we injected transgenic mice carrying *Apc* and/or *Arid1a* floxed genes with a low dose of Cre-expressing Adenovirus (AdCre) known to mainly target the liver (Colnot et al., 2004). In *Apc*-floxed mice, we previously showed that this dose was sufficient to induce  $\beta$ -catenin activation in single hepatocytes and promote tumorigenesis without killing the mice (Colnot et al., 2004). Accordingly, this injection in compound *Apc/Arid1a*-floxed mice inactivated both *Apc* and *Arid1a* genes in approximately 20% of hepatocytes ([*Apc-Arid1a*]<sup>ko-focal</sup> mice, Figure 1a, Figure 1—figure supplements 1).

Surprisingly, an ultrasound follow-up showed the development of striking echogenic features in [*Apc-Arid1a*]<sup>ko-focal</sup> mouse livers from 5 months after AdCre injection (Figure 1c, Figure 1—figure supplements 2a). We revealed after dissection that these livers harbored numerous and irregular dark red to black vascular lesions (Figure 1b). After 10 months, all [*Apc-Arid1a*]<sup>ko-focal</sup> mice (n = 24) exhibited blood-filled lacunar spaces (Figure 1c), as well as hepatomegaly (Figure 1—figure supplements 1a). We did not however observe such phenotypic abnormalities in the [*Apc*]<sup>ko-focal</sup> (n = 13), 18 [*Arid1a*]<sup>ko-focal</sup> (n = 18), or control (n = 10) mice studied. [*Apc-Arid1a*]<sup>ko-focal</sup> mice exhibited 50% and 100% mortality at 10 and 14 months, respectively (Figure 1d). In dying mice, we discovered that the whole liver was diseased and dark red in color. Indeed, the liver was filled with blood, harboring large necrotic areas with no remaining healthy zones (Figure 1d, inset).



**Figure 1.** Development of peliosis-like regions after hepato-specific and focal *Arid1a* and *Apc* inactivation. (a) Cre-loxP-generated hepatocyte-specific and inducible inactivation of *Apc* and/or *Arid1a* in 20% of hepatocytes after retro-orbital injection of infectious viral particles (ivp) of adenovirus encoding Cre recombinase (AdCre). The resulting mice are referred to as [Apc-Arid1a]<sup>ko-focal</sup>, [Apc]<sup>ko-focal</sup>, and [Arid1a]<sup>ko-focal</sup>. (b) Gross examination of mouse livers, 7 months after AdCre injection. Livers from [Apc-Arid1a]<sup>ko-focal</sup> mice had an irregular shape and a rough surface, with multiple dark red zones (indicated by arrows). (c) Incidence of hepatic lesions detected in WT (n = 10) and [Apc-Arid1a]<sup>ko-focal</sup> (n = 24) mice by ultrasonography. (d) Kaplan-Meier estimated survival curves of WT and [Apc-Arid1a]<sup>ko-focal</sup> mice over 15 months. n = 6 for each group. Inset: Liver of one mouse at necropsy (13 months after AdCre injection, representative of the three analyzed mice). (e) Hematoxylin Eosin (HE)-stained sections of mouse livers at 7 months post-injection. Large vascular spaces filled with blood cells were observed only in [Apc-Arid1a]<sup>ko-focal</sup> livers. Related data are found in **Figure 1—figure supplements 1–4**, and source data in **Figure 1—source data 1; Figure 1—figure supplement 1—source data 1; Figure 1—figure supplement 3—source data 1**.

The online version of this article includes the following source data and figure supplement(s) for figure 1:

Figure 1 continued on next page

Figure 1 continued

**Source data 1.** Emergence of peliosis (**Figure 1c**) and survival curve (**Figure 1d**).

**Figure supplement 1.** Focal inactivation of *Apc* and/or *Arid1a* genes in mouse liver.

**Figure supplement 1—source data 1.** Liver to body weight ratios (**Figure 1—figure supplements 1a**) and expression of *Glul* and *Axin2* mRNAs (**Figure 1—figure supplements 1b**).

**Figure supplement 2.** Ultrasound features of livers from seven-month-old [*Apc-Arid1a*]<sup>ko-focal</sup> mice.

**Figure supplement 3.** Blood vessel enrichment and angiogenesis in [*Apc-Arid1a*]<sup>ko-focal</sup> livers.

**Figure supplement 3—source data 1.** qPCR expression of angiogenic mRNAs (**Figure 1—figure supplements 3c**).

**Figure supplement 4.** Hepatocarcinogenesis in  $\beta$ -catenin-activated and *Arid1a*-null context.

Histologically, the diseased [*Apc-Arid1a*]<sup>ko-focal</sup> liver showed abnormal blood vessels that were partially or completely full of red blood cells (RBCs) (**Figure 1e**, **Figure 1—figure supplements 3a**), associated with sinusoidal dilatation and liver cell dropout. Additionally, using microbubble-assisted ultrasound, we showed a decrease in hepatic vascular perfusion within echogenic areas, illustrating hence a vascular liver disease (**Figure 1—figure supplements 2a**). We thus characterized these areas with dramatic histological features as peliosis-like areas, similar to the human vascular disease, peliosis.

In accordance with previous results (Colnot et al., 2004),  $\beta$ -catenin-activated liver tumors developed in 92% of [*Apc*]<sup>ko-focal</sup> mice (**Figure 1—figure supplements 4a**). Here, only 8% of [*Apc-Arid1a*]<sup>ko-focal</sup> mice developed liver tumors which were both  $\beta$ -catenin-activated and *Arid1a*-invalidated (**Figure 1—figure supplements 4a-c**), suggesting that *Arid1a* loss suppresses the tumorigenic effect of activated Wnt/ $\beta$ -catenin signaling in the liver. However, this model was not appropriate for assessing the effects of *Arid1a* loss on Wnt/ $\beta$ -catenin-dependent hepatocarcinogenesis in these mice, given the emergence of peliosis and lethality at a stage preceding or overlapping the expected tumor initiation phase (**Figure 1c**, **Figure 1—figure supplements 4a-c**).


We reveal here that  $\beta$ -catenin activation and *Arid1a* loss cooperate to induce a dramatic hepatic peliosis and lethality in the mouse.

## Hepatic loss of both *Arid1a* and *Apc* results in erythrocytosis linked to de novo transcription of *Epo*

We performed transcriptomic microarray analysis of micro-dissected [*Apc-Arid1a*]<sup>ko-focal</sup> livers (**Figure 2a**). Firstly, gene set enrichment analysis (GSEA) revealed transcriptional signatures linked to angiogenesis and the Erythropoietin (EPO) pathway in peliosis-like areas relative to adjacent regions (**Figure 2b,c** and **Figure 2—figure supplements 1**). Additionally, these peliosis-like regions showed a Wnt/ $\beta$ -catenin transcriptional signature, revealing enrichment of  $\beta$ -catenin-activated cells within these areas.

We then analyzed the hematological parameters and complete blood cell counts from peripheral blood. RBC counts, as well as hematocrit and hemoglobin levels, were significantly higher in [*Apc-Arid1a*]<sup>ko-focal</sup> mice than in control or single knockout mice (**Figure 2d**). This confirmed that blood erythrocytosis corresponded to erythrocyte overload.

The production of RBCs, known as erythropoiesis, is a dynamic process requiring the orchestration of specific molecular mechanisms (Nogueira-Pedro et al., 2016). These include for example the key EPO cytokine, a circulating glycoprotein hormone (Jelkmann, 2007). In mouse embryos, hepatoblasts are the primary source of Epo. In adults, the site of production switches from the liver to the kidney (Weidemann and Johnson, 2009), but the adult liver can still produce Epo (Suzuki, 2015). To determine whether erythrocytosis in [*Apc-Arid1a*]<sup>ko-focal</sup> mice could be due to dysregulation of this key hematological regulator, we examined *Epo* transcript and protein levels within the entire liver and the plasma fraction, respectively. We detected a marked reactivation of *Epo* expression in [*Apc-Arid1a*]<sup>ko-focal</sup> livers, whereas no *Epo* expression was detected in either single knockout or control livers (**Figure 2e**). This was associated with distinctly higher *Epo* protein levels in the plasma of [*Apc-Arid1a*]<sup>ko-focal</sup> mice (**Figure 2f**). We confirmed that plasma *Epo* derived from the liver as we observed no change in *Epo* transcription in the kidneys of [*Apc-Arid1a*]<sup>ko-focal</sup> mice (**Figure 2e**). Interestingly, we saw no changes in *Epo* mRNA levels in human HCC harboring the compound CTNNB1/*ARID1A* mutations (**Figure 1—figure supplements 4d**).



**Figure 2.** Hepatic peliosis has ‘angiogenic’ and ‘erythropoietin’ transcriptional signatures, linked to a systemic erythrocytosis and to de novo hepatic *Epo* expression in  $[Apc-Arid1a]^{ko-focal}$  mice. (a) Experimental strategy; (b) Transcriptomic gene-set enrichment analysis (GSEA) of hepatic peliosis ( $n = 4$ ) relative to adjacent regions ( $n = 4$ ) of  $[Apc-Arid1a]^{ko-focal}$  mice. (c) Quantitative RT-PCR showing relative expression of mRNAs for positive targets of hepatic Wnt/ $\beta$ -catenin pathway and angiogenic factors in hepatic peliosis ( $n = 10$ ) compared to adjacent regions ( $n = 10$ ) of  $[Apc-Arid1a]^{ko-focal}$  mice (unpaired t test analysis); (d) Hematological parameters from WT ( $n = 7$ ),  $[Apc]^{ko-focal}$  ( $n = 12$ ),  $[Arid1a]^{ko-focal}$  ( $n = 19$ ), and  $[Apc-Arid1a]^{ko-focal}$  ( $n = 20$ ) mice (One-way ANOVA analysis). (e) Evaluation of erythropoietin (*Epo*) mRNAs by quantitative RT-PCR in the livers analyzed by the  $\Delta$ Ct technique and expressed relative to those for 18S RNA for the liver, and as relative levels in the kidney (One-way ANOVA analysis). (f) Plasma EPO concentrations at sacrifice (WT ( $n = 6$ ),  $[Apc]^{ko-focal}$  ( $n = 5$ ),  $[Arid1a]^{ko-focal}$  ( $n = 2$ ), and  $[Apc-Arid1a]^{ko-focal}$  ( $n = 10$ )). Exact p-values are mentioned, \*\*\*\* $p < 0.0001$ . Related data are found in **Figure 2—figure supplements 1** and source data in **‘Figure 2—source data 1’**.

Figure 2 continued on next page

Figure 2 continued

The online version of this article includes the following source data and figure supplement(s) for figure 2:

**Source data 1.** Gene expression (**Figure 2c, e**) and hematological parameters (**Figure 2d**).

**Figure supplement 1.** Peliosis-like regions from  $[Apc-Arid1a]^{ko-focal}$  livers are enriched for 'Endothelium development' and 'Erythrocyte homeostasis' transcriptional signatures.

Overall, our findings demonstrate that simultaneous *Arid1a* loss and  $\beta$ -catenin activation in single hepatocytes, occurring in a physiological but non-cancerous context, are responsible for a major hematological disorder that is linked to de novo expression and subsequent secretion of hepatic Epo.

### Erythropoiesis is induced in the spleens of $[Apc-Arid1a]^{ko-focal}$ mice

To determine the site of pathological production of the RBCs observed in  $[Apc-Arid1a]^{ko-focal}$  mice, we examined the liver, bone marrow (BM), and spleen; these are the three major organs responsible for erythropoiesis during embryogenesis (*Suzuki et al., 2011*), adult life (*Suzuki, 2015*), and stress responses in mice (*Perry et al., 2009*), respectively. Firstly, gross dissection of  $[Apc-Arid1a]^{ko-focal}$  mice revealed a marked splenomegaly (**Figure 3a,b**). Histological sections from  $[Apc-Arid1a]^{ko-focal}$  spleens showed prominent expansion of the red pulp with a predominance of erythroblasts relative to control spleens (**Figure 3c**).


We additionally quantified erythroid precursors in the liver, BM, and spleen by flow cytometry (corresponding to the TER119<sup>+</sup>/CD71<sup>+</sup> cell population). In  $[Apc-Arid1a]^{ko-focal}$  liver non-parenchymal cells (NPCs) relative to controls, there was no difference in TER119<sup>+</sup>/CD71<sup>+</sup> progenitors revealing no intra-hepatic erythropoiesis (**Figure 3d,e**). However, there was a striking increase in the RBC population (TER119<sup>+</sup>/CD71<sup>+</sup>). This liver erythrocytosis was confirmed by immunostaining of the hemoglobin subunit beta (HBB) in liver tissue sections, showing that RBCs, but not erythroblasts, accumulated in these livers (**Figure 3—figure supplements 1**). In addition, TER119<sup>+</sup>/CD71<sup>+</sup> cell populations were similar in the BM of  $[Apc-Arid1a]^{ko-focal}$  and control mice, whereas we found threefold more erythroid precursors in  $[Apc-Arid1a]^{ko-focal}$  spleens than in control spleens (**Figure 3d,e**). This suggested that RBC overproduction came from splenic and not from medullary or hepatic erythroblasts. We then analyzed the ability of erythroid progenitors to expand by in vitro quantification of erythroid colony-forming units (CFU-E) from spleen cells, BM cells, and liver NPCs. We confirmed the presence of erythroid progenitors in the BM and spleens of control mice after 3 days of culture in the presence of EPO, and their absence in control liver NPCs (**Figure 3f**). After EPO treatment, the spleens of  $[Apc-Arid1a]^{ko-focal}$  mice contained 13-fold more CFU-E than control spleens (**Figure 3f**). This was not the case for the liver or BM. Finally, there were higher mRNA levels of erythropoiesis-related signaling components (*Nogueira-Pedro et al., 2016*) in the spleens of  $[Apc-Arid1a]^{ko-focal}$  mice than those of control or single knockout mice (**Figure 3g**), including that of the Epo receptor.

Overall, these data show a strong increase in erythropoiesis and erythrocyte progenitors in the spleens of  $[Apc-Arid1a]^{ko-focal}$  mice.

### Blocking Epo signaling reverses erythrocytosis and splenic erythropoiesis, but maintains liver angiogenesis

We analyzed the role of Epo in the dramatic phenotype of  $[Apc-Arid1a]^{ko-focal}$  mice. We used an anti-EPO blocking serum which neutralizes soluble erythropoietin in mice (*Mastrogiannaki et al., 2012*). Anti-Epo treatment restored the hematocrit level of  $[Apc-Arid1a]^{ko-focal}$  mice to that of untreated controls (**Figure 4a, Figure 2d**), showing a reversal of blood erythrocytosis. We quantified 10-fold less erythroid precursors and a lower mRNA expression of erythropoiesis factors in the spleen of anti-Epo treated  $[Apc-Arid1a]^{ko-focal}$  mice compared to untreated mice (**Figure 4b–d**).

EPO is a pleiotropic growth factor which can stimulate vessel growth through an autocrine and/or paracrine loop (*Kimáková et al., 2017*). We tested the attractive possibility that hepatocyte-secreted Epo in  $[Apc-Arid1a]^{ko-focal}$  mouse livers regulates RBC homing to the liver through increased angiogenesis. Liver tissue sections showed that blood vessels contained less RBCs in anti-EPO treated  $[Apc-Arid1a]^{ko-focal}$  mice compared to untreated mice (**Figure 4e, Figure 4—figure supplements 1**), and these livers harbored less TER119<sup>+</sup>/CD71<sup>+</sup> mature RBCs (**Figure 4f–g**). Despite




**Figure 3.** Erythropoiesis occurs in the spleen of [Apc-Arid1a]<sup>ko-focal</sup> mice. (a) Gross morphology of spleens from representative control (WT) and [Apc-Arid1a]<sup>ko-focal</sup> mice; (b) Spleen/body weight ratio of WT (n = 7), [Apc]<sup>ko-focal</sup> (n = 11), [Arid1a]<sup>ko-focal</sup> (n = 11), and [Apc-Arid1a]<sup>ko-focal</sup> (n = 17) mice (one-way ANOVA). (c) Hematoxylin and Eosin staining of splenic sections. Scale bar is 200 μm. (d,e) FACS analysis of liver NPC, bone marrow, and spleens from control (WT) or [Apc-Arid1a]<sup>ko-focal</sup> mice using the erythroid markers CD71 and Ter119. (e) FACS quantification from WT (n = 4) and [Apc-Arid1a]<sup>ko-focal</sup> (n = 4) mice (multiple t-test). (f) Quantification of erythroid progenitors as erythroid colony-forming units (CFU-E) in the presence of EPO, using 2 × 10<sup>5</sup> cells from bone marrow or 2 × 10<sup>6</sup> cells from the liver and spleen of WT or [Apc-Arid1a]<sup>ko-focal</sup> mice (2-way ANOVA). (g) Q-PCR showing relative expression of several factors, known to be involved in stress-induced erythropoiesis, in the spleens of WT (n = 9), [Apc]<sup>ko-focal</sup> (n = 5), [Arid1a]<sup>ko-focal</sup> (n = 8), and [Apc-Arid1a]<sup>ko-focal</sup> (n = 8) mice (one-way ANOVA). \*\*\*\*p < 0.0001. Related data are found in **Figure 3—figure supplements 1** and source data in **'Figure 3—source data 1'**.

The online version of this article includes the following source data and figure supplement(s) for figure 3:

**Source data 1.** Spleen to body weight (**Figure 3b**), FACS analyses (**Figure 3e**), CFU-E counts (**Figure 3f**) and gene expression (**Figure 3g**).

**Figure supplement 1.** Hepato-specific and focal inactivation of Apc and Arid1a genes leads to sequestration of enucleated beta-globin-positive red blood cells.



**Figure 4.** Blockade of Epo signaling with anti-EPO serum in  $[Apc-Arid1a]^{ko-focal}$  mice eliminates aberrant erythropoiesis in the spleen, but maintains angiogenesis in the liver. (a) Hematocrit before (n = 4) and after (n = 4) anti-EPO treatment (t-test). (b,c) FACS analysis (b) and quantification (c) of spleens with/without anti-EPO (n = 4 for each group) (t-test). (d) RT-qPCR showing relative expression of erythropoiesis factors in the spleens of WT (n = 9), treated  $[Apc-Arid1a]^{ko-focal}$  (n = 4), untreated  $[Apc-Arid1a]^{ko-focal}$  (n = 8) mice (one-way ANOVA). (e) Hematoxylin Eosin (HE)-stained sections of livers from representative 7-month-old mice. (f,g) FACS analysis (f) and quantification (g) of liver NPC with/without anti-EPO. (h) RT-qPCR showing relative expression of angiogenic factors in the livers with (n = 4) and without (n = 10) anti-EPO (t-test). \*\*\*\*p < 0.0001. Related data are found in **Figure 4—figure supplements 1** and source data in '**Figure 4—source data 1**'.

The online version of this article includes the following source data and figure supplement(s) for figure 4:

**Source data 1.** Hematocrit (**Figure 4a**), FACS quantifications (**Figure 4c, g**) and gene expression (**Figure 4d, h**) after anti-EPO treatment.

**Figure supplement 1.** Anti-EPO blocking serum treatment in  $[Apc-Arid1a]^{ko-focal}$  mice leads to decrease of intra-hepatic red blood cells accumulation.

this decrease in intrahepatic RBCs, we did not observe any change in the disruption of the liver vascular architecture as shown by both histological (**Figure 4e**, **Figure 4—figure supplements 1**) and gene expression analyses (**Figure 4h**).

We demonstrate here that high plasma Epo concentration is directly responsible for splenic erythropoiesis and erythrocytosis in  $[Apc-Arid1a]^{ko-focal}$  mice. However, this cytokine alone is not responsible for alterations in liver angiogenesis.

### **Epo is cell-autonomously expressed by $\beta$ -catenin-activated *Arid1a*-null hepatocytes in both the mouse and in humans**

We investigated whether *Epo* is expressed by hepatocytes after *Apc* and/or *Arid1a* hepato-specific inactivations. We generated Tamoxifen-induced mouse models (**Figure 5a**) with short-term panlobular gene inactivations (**Figure 5b**) and *Apc* loss-induced hepatomegaly (**Figure 5—figure supplements 1a**) as previously shown (**Buenrostro et al., 2015**). After diet-based Tamoxifen administration, the *Apc* and/or *Arid1a* genes were invalidated in approximately 90% of hepatocytes (**Figure 5—figure supplements 1b**). There was no gene invalidation in liver NPCs, thus highlighting the high purity of the NPC fraction (**Figure 5—figure supplements 2a**). We detected *Epo* mRNA expression only in the hepatocyte compartment and not in NPCs of  $[Apc-Arid1a]^{ko-TOTAL}$  livers, whereas a slight decrease of *Epo* expression was seen in the kidney of  $[Apc-Arid1a]^{ko-TOTAL}$  mice (**Figure 5c,d**).

To confirm the cell-autonomous expression of *Epo* in  $\beta$ -catenin-activated *Arid1a*-null hepatocytes, we performed RNA in situ hybridization for *Epo* with *Axin2* as a marker of  $\beta$ -catenin activation (**Figure 6**). *Epo* transcripts were not expressed in the livers, yet were abundant in rare interstitial renal cells of control mice (**Figure 6—figure supplements 1a**); this localization of *Epo* in the kidney has already been described (**Lacombe et al., 1988**). Conversely but as expected, we found *Axin2* mRNA transcripts in pericentral hepatocytes (**Benhamouche et al., 2006**). After *Apc* and *Arid1a* gene invalidation, we found a de novo expression of *Epo* in a subset of *Axin2*-expressing hepatocytes. In the long-term focal model, this expression was restricted to the areas of peliosis (**Figure 6a**). In the short-term panlobular model, rare *Axin2*-expressing hepatocytes also expressed single *Epo* mRNA transcripts (**Figure 6b**). In both models, *Epo* expression was not found elsewhere in the liver.


We examined whether *Epo* expression is specific to the loss of *Apc* or can be initiated regardless of how Wnt/ $\beta$ -catenin signaling is activated. We successfully activated  $\beta$ -catenin via its Wnt/Spondin ligand in murine primary hepatocytes (**Figure 5—figure supplements 2e**). We consecutively performed in vivo *Arid1a* knockout followed by in vitro Wnt/Spondin stimulation, or in vivo *Apc* loss followed by efficient in vitro siRNA-mediated *Arid1a* knockdown (si-*Arid1a*) (**Figure 5—figure supplements 2f**). *Epo* expression significantly increased in these conditions (**Figure 5e**, **Figure 5—figure supplements 2b, c**). Mutational activation of  $\beta$ -catenin coupled with si-*Arid1a* also led to the induction of *Epo* expression in the  $\beta$ -catenin-mutated HEPA1.6 murine hepatoma-derived cell line (**Figure 5—figure supplements 2d**).

We assessed the conservation of EPO regulation from mouse to humans. We found that *EPO* mRNA expression was also regulated by both the chromatin remodeler ARID1A and the Wnt/ $\beta$ -catenin signaling pathway in primary human hepatocytes after siRNA-mediated ARID1A and APC down-regulation (**Figure 5f**).

Overall, these in vivo and in vitro findings strongly demonstrate a conserved and cell-autonomous role of Wnt/ $\beta$ -catenin activation and *Arid1a* loss in hepatic *Epo* expression. This occurs as a stochastic transcriptional event in  $\beta$ -catenin-activated *Arid1a*-null hepatocytes.

### **Wnt/ $\beta$ -catenin pathway control of 3' *Epo* enhancer activity is hypoxia- and HIF-independent**

We questioned if  $\beta$ -catenin directly controls *Epo* transcription through cis-regulatory sequences. We previously performed ChIP-Seq experiments to assess Tcf4/ $\beta$ -catenin occupancy in the chromatin of hepatocytes isolated from  $[Apc]^{ko-TOTAL}$  versus  $[\beta\text{-catenin}]^{ko-TOTAL}$  murine models (**Gougelet et al., 2014**). The only DNA region bound by Tcf4 in the vicinity of the *Epo* gene was its 3' enhancer (*Epo*-3'E), known to be involved in *Epo* transcription in the embryonic liver, as well as the known Hif- (HIF-REs) and Hnf4-containing responses elements (HREs) (**Suzuki et al., 2011**; **Semenza et al., 1991**; **Figure 7a**). This Tcf4 binding was at the same location as HRE binding, and was stronger in activated



**Figure 5.** Cell-autonomous *Epo* expression after *Arid1a* inactivation and Wnt/ $\beta$ -catenin activation in murine and human hepatocytes. (a) In vivo and ex vivo strategy. WT (n = 8), [*Apc*]<sup>ko-TOTAL</sup> (n = 7), [*Arid1a*]<sup>ko-TOTAL</sup> (n = 8), and [*Apc-Arid1a*]<sup>ko-TOTAL</sup> (n = 10) mice. (b) Inactivation efficiency of *Apc* and *Arid1a* genes in isolated hepatocytes. (c,d) RT-qPCR assessment of erythropoietin (*Epo*) transcription (c) in the hepatocyte and NPC compartments of the livers, (d) in the kidney (1-way ANOVA). (e) In vitro analysis of *Axin2*, *Arid1a* (*Arid1a* floxed-exon detection), and *Epo* expression by RT-qPCR of mouse hepatocytes after Wnt3a and R-Spondin3 stimulation, and si-*Arid1a*/si-Control treatments, showing *Arid1a* knockdown efficiency and Wnt/ $\beta$ -catenin pathway activation, as the mRNA levels of *Axin2*, a canonical target gene of Wnt signaling, significantly increased (2-way ANOVA). (f) In vitro analysis of *Apc*, *Arid1a*, and *Epo* by RT-qPCR of cryopreserved human hepatocytes after siRNA transfection (one-way ANOVA analysis). Data are presented as the mean  $\pm$  SEM. \*\*\*\*p < 0.0001. Cell culture data are representative of three independent experiments. Related data are found in **Figure 5—figure supplements 1–2**, and source data in **‘Figure 5—source data 1; Figure 5—figure supplement 1—source data 1; Figure 5—figure supplement 2—source data 1’**.

The online version of this article includes the following source data and figure supplement(s) for figure 5:

**Source data 1.** Efficiency of gene invalidation (**Figure 5b**), and gene expression in vivo and ex vivo (**Figure 5c-f**) in mice and humans.

**Figure supplement 1.** Panlobular inactivation of *Apc* and/or *Arid1a* in hepatocytes.

**Figure supplement 1—source data 1.** Liver to body weight ratio (**Figure 5—figure supplements 1a**).

**Figure supplement 2.** Cell-autonomous *Epo* expression after *Arid1a* invalidation and Wnt/ $\beta$ -catenin activation in hepatocytes.

Figure 5 continued on next page

Figure 5 continued

**Figure supplement 2—source data 1.** Efficiency of gene invalidation (**Figure 5—figure supplements 2a**), mRNA expression (**Figure 5—figure supplements 2b-d**), western blots (**Figure 5—figure supplements 2e**).

$\beta$ -catenin than in  $\beta$ -catenin-null hepatocytes (**Figure 7a**). We demonstrated from ENCODE data that H3K27Ac, a histone mark indicating active promoters or enhancers, also bound to this region; this binding was present in mouse liver chromatin at E14.5, an embryonic stage in which the *Epo* gene is actively transcribed (**Figure 7a**). However, *Epo* was only partially present in the livers of eight-week-old mice, with no *Epo* transcription, and completely absent in the adult small intestine, a tissue known not to transcribe the *Epo* gene (**Figure 7a**).

We thus tested whether Wnt/ $\beta$ -catenin signaling directly activates hepatic *Epo* transcription through the *Epo*-3'E. We transfected a luciferase reporter (pEpoE-luc) containing the HIF and HNF4-binding sites into primary mouse hepatocytes (**Figure 7b**). After Wnt/Spondin stimulation, and regardless of si-*Arid1a* treatment, *Epo* enhancer activity was five- to eight-fold higher (**Figure 7c,d**). Hence, in this in vitro reporter assay context,  $\beta$ -catenin signaling increases *Epo*-3'E activity and it is independent of the chromatin landscape.

Hypoxia-inducible factor (HIF) signaling is the master pathway regulating *EPO* transcription and Hif2 $\alpha$  has a prominent role in hepatic *Epo* transcription (**Mastrogiannaki et al., 2012**). We investigated Hif2 $\alpha$  involvement in  $\beta$ -catenin/*Arid1a*-dependent *Epo* expression. In vivo, we did not detect hypoxia or Hif1 $\alpha$ /Hif2 $\alpha$  accumulation in the absence of *Apc* and/or *Arid1a* in mouse livers (**Figure 7—figure supplements 1a-c**). A small subset of Hif1 $\alpha$ /Hif2 $\alpha$  targets, such as *Eno2*, *Car9*, and *Rab42*, was slightly overexpressed in both [Apc]<sup>ko</sup> and [Apc-*Arid1a*]<sup>ko</sup> livers, confirming that  $\beta$ -catenin and HIF signaling share some transcriptional targets (**Figure 7—figure supplements 1d-e; Benhamouche et al., 2006**). As expected, the hypoxia-mimetic agent desferrioxamine (DFO) markedly potentiated luciferase activity in pEpoE-luc-transfected hepatocytes, whereas efficient knockdown of both *Hif1 $\alpha$*  or *Hif2 $\alpha$*  (**Figure 7—figure supplements 2**) resulted in a significant decrease (**Figure 7e**). Interestingly, knockdown of *HIFs*, either alone or combined, did not reduce *Epo*-3'E induction by  $\beta$ -catenin signaling in hepatocytes, whether *Apc* be inactivated alone or in combination with *Arid1a* (**Figure 7e**).

In all, the Wnt/ $\beta$ -catenin pathway controls erythropoietin expression in hepatocytes through the 3' *Epo* enhancer in a hypoxia- and HIF-independent manner.


### Both $\beta$ -catenin signaling and *Arid1a* are key players in chromatin remodeling, histone recruitment, and Tcf4 binding on the hepatic *Epo* enhancer

We previously showed similarities between HREs and WREs, and that Tcf4 can bind HREs and thereby participate in  $\beta$ -catenin-dependent transcription (**Gougelet et al., 2014**). Here, we found that Tcf4 bound DNA on the HRE region of the *Epo*-3'E in which there is no classical WRE. Indeed, by electrophoretic mobility shift assay (EMSA), we showed that Tcf4 weakly bound the *Epo*-3'E HRE (thereafter called DR2) in control liver nuclear extracts (**Figure 8a**). In [Apc]<sup>ko-TOTAL</sup> liver extracts, the nuclear translocation of  $\beta$ -catenin led to a stronger binding represented by a supershift (**Figure 8a, b**). This indicates that the Tcf4/ $\beta$ -catenin complex binds this DR2 motif, as well as a classical WRE shown by competitive EMSA (**Figure 8b,c**). These findings highlighted that Tcf4 binds to the HRE of the *Epo* enhancer and that activation of  $\beta$ -catenin increases this interaction.

Endogenous hepatic *Epo* was expressed de novo after both Wnt/ $\beta$ -catenin activation and *Arid1a* knockout, but gene expression of classical  $\beta$ -catenin target genes (*Glul*, *Axin2*) was not affected by *Arid1a* status (**Figure 8—figure supplements 1**). We thus characterized Tcf4 binding, chromatin accessibility, and histone active (H3K27Ac) or repressive (H3K27Me3) marks of the *Epo* enhancer, the *Axin2* intronic enhancer, and the *Glul* promoter in hepatocytes isolated from transgenic mouse livers.

As previously described (**Gougelet et al., 2014**), Tcf4 efficiently bound to the *Axin2* intronic enhancer in vivo and this increased when  $\beta$ -catenin signaling was activated (**Figure 8d**). This was





**Figure 7.** Wnt/ $\beta$ -catenin directly controls EPO expression through 3' *Epo* enhancer, in a HIF-independent manner. (a) Genomic environment of the *Epo* gene (UCSC Genome Browser, mm9 database) and ChIP-seq peaks at the 3' *Epo* enhancer. In blue/red: the crude reads of ChIP-Seq data performed in adult livers against HNF-4 $\alpha$  (54). In black: ChIP-Seq under *Apc*<sup>ko</sup> or  $\beta$ cat<sup>ko</sup> conditions with an antibody against TCF4 (16). In yellow: ENCODE data of H3K27Ac marks in eight-week-old and E14.5 embryonic livers (Histone Mods by ChIP-Seq from ENCODE/LICR). (b) Schematic representation of the reporter construct. (c) Relative EpoE-LUC induction in WT, siCtrl, Wnt3a RSp03, and siArid1a. (d) Relative EpoE-LUC induction in WT, [Apc]<sup>ko</sup>, [Arid1a]<sup>ko</sup>, and [Apc-Arid1a]<sup>ko</sup>. (e) Relative EpoE-LUC induction in -DFO and +DFO conditions for WT, [Apc]<sup>ko</sup>, [Arid1a]<sup>ko</sup>, and [Apc-Arid1a]<sup>ko</sup>, with various siRNA treatments.

Figure 7 continued

EpoE-Luc erythropoietin luciferase reporter, driven by the 3' enhancer. (c–e) Luciferase reporter assays in mouse primary hepatocytes: (c) after in vitro overactivation of Wnt/ $\beta$ -catenin signaling and Arid1a knockdown (d) after in vivo Cre-loxP-mediated gene inactivation; (e) Effect of hypoxic-mimic conditions using desferrioxamine (DFO), and effect of knockdown of HIF factors (two separate experiments carried out in triplicate). Results are in relative light units, and analyzed using 1-way (d) or 2-way ANOVA (c,e). \*\*\*\* $p < 0.0001$ . Related data are found in **Figure 7—figure supplements 1–2**, and source data in '**Figure 7—source data 1**'; **Figure 7—figure supplement 1—source data 1**; **Figure 7—figure supplement 2—source data 1**'. The online version of this article includes the following source data and figure supplement(s) for figure 7:

**Source data 1.** EpoE-luc luciferase relative activity (**Figure 7c–e**).

**Figure supplement 1.** Lack of hypoxia and HIF signaling in [*Apc-Arid1a*]<sup>ko-TOTAL</sup> livers.

**Figure supplement 1—source data 1.** Quantification of western blots (**Figure 7—figure supplements 1c**) and mRNA expression (**Figure 7—figure supplements 1d–e**).

**Figure supplement 2.** Effect of HIF1 $\alpha$  and HIF2 $\alpha$  knock-downs in mouse primary and transgenic hepatocytes.

**Figure supplement 2—source data 1.** mRNA expressions (**Figure 7—figure supplements 2a, c, d**) and western blots (**Figure 7—figure supplements 2b, e**).

correlated with a partial removal of the repressive H3K27Me3 mark (**Figure 8d**) and an increase in chromatin accessibility revealed by ATAC-qPCR analysis (**Figure 8f**). Co-inactivation of *Arid1a* and *Apc* decreased chromatin accessibility on this enhancer and induced a H3K27me3 repressive histone mark. A similar chromatin accessibility profile was seen for the *Glul* promoter. Tcf4 bound in vivo to the *Epo* enhancer, and this binding was slightly higher in [*Apc*]<sup>ko-TOTAL</sup> and much higher in [*Apc-Arid1a*]<sup>ko-TOTAL</sup> hepatocytes versus controls (**Figure 8e**). After *Apc* loss, the H3K27me3 repressive mark slightly decreased on *Epo* enhancer and chromatin was more accessible (**Figure 8f**, **Figure 8—figure supplements 1b**). In contrast, the loss of *Arid1a* strongly decreased the H3K27Me3 repressive mark without modifying chromatin access. In [*Apc-Arid1a*]<sup>ko-TOTAL</sup> hepatocytes, the H3K27Ac active histone mark was induced while chromatin accessibility was lower compared to single knockout hepatocytes.


These data show that nuclear  $\beta$ -catenin favors Tcf4 binding on the *Epo* enhancer, increasing its chromatin accessibility, whereas *Arid1a* loss rather disrupts the H3K27me3 histone repressive mark. Both these changes increase the H3K27Ac enhancer mark and promote hepatic *Epo* transcription (**Figure 9**).

## Discussion

Our study shows that the *Arid1a*-dependent epigenetic landscape in the adult liver is a potent brake for transcription of *EPO*, a new key  $\beta$ -catenin target (**Figure 9**). Consequently, *Arid1a* loss in the context of  $\beta$ -catenin activation leads to *Epo*-dependent erythropoiesis in the spleen, erythrocytosis in the blood and liver, and to increased but defective angiogenesis, generating 'peliosis'.

Liver peliosis is a misunderstood human vascular disease, with non-specific features of impaired blood inflow and/or systemic inflammatory response (**Valla and Cazals-Hatem, 2018**). The dramatic phenotype we observed here is distinct from other existing murine models of liver-induced hypoxia with equivalent non-lethal erythrocytosis (**Minamishima and Kaelin, 2010**; **Ruschitzka et al., 2000**; **Takeda et al., 2008**). Using an anti-*Epo* blocking strategy, we could explain this discrepancy: our phenotypic observations were attributable to not only *Epo*-dependent erythrocytosis, as restricting plasma *Epo* rescued the erythrocytosis phenotype, but also to *Epo*-independent aberrant angiogenesis, a hallmark of liver peliosis (**Valla and Cazals-Hatem, 2018**).

We describe emerging roles for ARID1A and  $\beta$ -catenin signalings in *Epo* transcription. Until now, the major known regulator of both renal and hepatic *Epo* transcription was hypoxia-inducible factor signaling, acting via *EPO*'s 3' enhancer (*Epo*-3'E) in the embryonic liver or anemic/hypoxic adult liver. We demonstrated that Tcf4/ $\beta$ -catenin bound the Hnf4-Responsive Element (Hnf4-RE) in the *Epo*-3'E and that the enhancer activity is independent of HIF in this context, contrary to what is reported in colorectal cancer cell lines, in which transcriptional cooperation between HIF and  $\beta$ -catenin occurs in hypoxia adaptation (**Kaidi et al., 2007**).



**Figure 8.**  $\beta$ -catenin/Tcf4 complex binds to the HNF4-responsive element of Epo enhancer (Epo-HRE) after modifications of histone marks and chromatin accessibility. (a) EMSA using nuclear proteic extracts from WT or [Apc]<sup>ko-TOTAL</sup> livers and <sup>32</sup>P-labeled probes containing Epo-HRE (DR2). (b, c) Competitive EMSA using <sup>32</sup>P-labeled DR2 (b) and <sup>32</sup>P-labeled WRE (c) probes and increasing concentrations of cold probes containing HNF4, WRE or control-responsive element. WRE cold probes compete with radiolabeled DR2 motif for the Tcf4/ $\beta$ -catenin binding and vice versa. (d, e) Chromatin ImmunoPrecipitation (ChIP) assays of hepatocytes from WT, [Apc]<sup>ko-TOTAL</sup>, [Arid1a]<sup>ko-TOTAL</sup>, and [Apc-Arid1a]<sup>ko-TOTAL</sup> livers. ChIP-qPCR against IgG, Tcf4, Acetylation of Histone3 in Lysine27 (H3K27Ac), and Tri-methylation of Histone3 in Lysine27 (H3K27me3) for Axin2 (d) and Epo (e) enhancer regions. WT (n = 3), [Apc]<sup>ko-TOTAL</sup> (n = 2), [Arid1a]<sup>ko-TOTAL</sup> (n = 2), and [Apc-Arid1a]<sup>ko-TOTAL</sup> (n = 3) mice. Enrichment by ChIP was assessed relative to the input DNA and normalized to the level of negative controls. (f) ATAC-qPCR using frozen livers from WT (n = 7), [Apc]<sup>ko-TOTAL</sup> (n = 7), [Arid1a]<sup>ko-TOTAL</sup> (n = 6), and [Apc-Arid1a]<sup>ko-TOTAL</sup> (n = 7) mice. Data are analyzed with one-way ANOVA. \*\*\*\*p<0.0001. Related data are found in **Figure 8—figure supplements 1–2**, and source data in **Figure 8—source data 1; Figure 8—figure supplement 2—source data 1; Figure 8—figure supplement 2—source data 1**.

The online version of this article includes the following source data and figure supplement(s) for figure 8:


**Source data 1.** EMSA (**Figure 8a-c**), ChIP-qPCR (**Figure 8d, e**) and ATAC-qPCR (**Figure 8f**) data.

**Figure supplement 1.** The expression of  $\beta$ -catenin-positive target genes is not modulated by Arid1a status.

**Figure supplement 1—source data 1.** mRNA expression (**Figure 8—figure supplements 1a**).

**Figure supplement 2.** Chromatin accessibility assessed all along the hepatic 3'Epo enhancer by ATAC-qPCR.

**Figure supplement 2—source data 1.** ATAC-qPCR data (**Figure 8—figure supplements 2b**).



**Figure 9.** Schematic model of the role of *Arid1a* in hepatic *Epo* expression linked to overactivation of the Wnt/β-catenin pathway. Under physiological conditions, the presence of *Arid1a* is associated with histone repressive marks at the *Epo* enhancer and β-catenin is constantly degraded; thus, *Epo* is not produced. In the absence of *Apc*, β-catenin/Tcf4 complex binds the *Epo* enhancer, and enhances chromatin accessibility, but the histone marks remain repressive. The loss of *Arid1a* increases active histone marks, which is insufficient to induce *Epo* transcription. After both Wnt/β-catenin activation and *Arid1a* inactivation, active histone marks and binding of β-catenin/Tcf4 to the *Epo* enhancer drive *Epo* liver transcription, and subsequent secretion of *Epo* into the bloodstream, resulting in splenic erythropoiesis and in substantial blood and liver erythrocytosis.

The consequences of this HIF signaling-independent *Epo* regulation is significant for the genetic engineering of EPO for therapeutic purposes. In anemia, a major complication of chronic kidney disease, HIF stabilizers are currently used to restore circulating EPO levels. The long-term safety of this strategy is hindered by the lack of targeting specificity (Kular and Macdougall, 2019). The use of cell transcriptional machinery to produce therapeutic levels of EPO has been put forward to overcome the side effects associated with HIF stabilizers. The EPO-producing cells of the adult kidney are potential candidates, but anemic patients have damaged kidneys. Based on our results, here we

can propose an alternative involving the restoration of the ability of hepatocytes to synthesize EPO, independently of hypoxia, by targeting Wnt/ $\beta$ -catenin and ARID1A signaling in the liver.

Our demonstration that *Arid1a* inactivation is required in *Epo* transcription opposes previously described roles of chromatin remodeling complexes in hepatic regulation of *Epo* (Wang et al., 2004; Sena et al., 2013). However, firstly these studies analyzed hypoxia-dependent *Epo* regulation which is distinct from our study; we firmly established that the  $\beta$ -catenin-dependent control of *Epo* transcription depends on *Arid1a* loss, is Hif-independent, and occurs in a normoxic adult liver. Secondly, these studies focused on BRG1/BRM ATPases, essential core subunits of both the BAF and pBAF complexes. The loss of *Arid1a*, a facultative component of the BAF complex, does not disrupt BAF complex functionality as *Arid1b* is known to compensate for *Arid1a* loss. This highlights a specific role for *Arid1a* in transcriptional repression through the modulation of chromatin accessibility to transcription factors at their target DNA sequences (Sun et al., 2016; Nagl et al., 2005). We show increased binding of the Tcf4/ $\beta$ -catenin complex to *Epo*-3'E Hnf4-RE is *Arid1a*-dependent and *Arid1a* loss decreases the H3K27me3 repressive mark. That could be due to the intricate balance existing between the Polycomb complex PRC2 and the SWI/SNF complex (Kadoch et al., 2016). Accordingly, the inhibition of the Polycomb EZH2 subunit is synthetically lethal in ARID1A-mutated tumors (Bitler et al., 2015; Alldredge and Eskander, 2017). Therefore, *Arid1a* and the Polycomb complex could act in concert to modulate *Epo* gene expression in the liver.

We illustrate that *Arid1a* loss renders the liver *Epo*-inducible element more accessible to Tcf4, and even more so to  $\beta$ -catenin. Contrary to the paradigm that Tcf4 binds its DNA targets regardless of  $\beta$ -catenin activation status, we previously reported that Tcf4 DNA-binding was stronger in the presence of nuclear  $\beta$ -catenin in the liver (Gougelet et al., 2014). More broadly, numerous interactions between chromatin remodeling and Wnt/ $\beta$ -catenin signaling have already been described (Barker et al., 2001; Eckey et al., 2012; Mathur et al., 2017; Song et al., 2009; Yan et al., 2014; Zhai et al., 2016) and can explain the impact of  $\beta$ -catenin signaling on chromatin accessibility at the *Epo* enhancer. Single-RNA in situ hybridization revealed that *Epo* gene expression only occurs in rare hepatocytes, emphasizing the complexity of *Epo* liver transcription in the liver. This contributes to previous studies using single-RNA in situ hybridization, showing that transcription in the liver is gene-dependent, and is either bursty and dynamic or stable (Bahar Halpern et al., 2015).

We found here that the loss of *Arid1a* does not change the transcription of hepatic canonical Wnt/ $\beta$ -catenin target genes. As for *Epo*, it could potentially unmask new chromatin-dependent  $\beta$ -catenin target genes. Among these new *Arid1a*/ $\beta$ -catenin target genes are those involved in liver angiogenesis. In the near future, genome-wide studies will be required to firmly identify these genes, combining the analysis of transcriptome, chromatin accessibility (ATAC-Seq), histone mark,  $\beta$ -catenin and *Arid1a* cistromes (ChIP-Seq) in liver chromatin from *Arid1a*-null and  $\beta$ -catenin-activated hepatocytes.

The initial aim of our study was to better elucidate oncogenic cooperation in liver carcinogenesis. In our in vivo experimental models reported here, the loss of *Arid1a* protects against  $\beta$ -catenin-dependent carcinogenesis. However, these results were not fully exploitable due to the deleterious effect of the dramatic hematological disorder developed by the mice. New mouse models are therefore required for further investigation of the oncogenic role of *Arid1a* in liver carcinogenesis. In turn, confirmation of such a role would corroborate a recent study showing that hepatic *Arid1a* can harbor either a tumor suppressor or oncogenic role depending on the cellular context (Sun et al., 2018). An additional study also demonstrated that *Arid1a* is protumoral rather than a tumor suppressor in colorectal cancer with *Apc* mutations (Mathur et al., 2017).

Lastly, some liver cancer studies have identified pathological erythrocytosis and/or hepatic vascular lesions, potentially with EPO production and peliosis. However, the molecular mechanisms underlying these pathological observations are still poorly understood (Matsuyama et al., 2000; Bunn, 2013; Ke et al., 2017; Hoshimoto et al., 2009; Tsuchiya et al., 2009; Vik et al., 2009). Our study contributes molecular clues by indicating that this is not linked to CTNNB1/ARID1A mutations, but more likely attributed to the hypoxia frequently found in cancers. Future studies should use mouse models and data from patients with HCC to address the specific transcriptional output of CTNNB1/ARID1A-mutated liver tumors.

## Materials and methods

## Key resources table

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Gene ( <i>Mus musculus</i> )	Epo	GenBank	NM_007942.2	Erythropoietin
Gene ( <i>Mus musculus</i> )	Arid1a	GenBank	NM_001080819.2	Arid1a
Gene ( <i>Mus musculus</i> )	Ctnnb1	GenBank	NM_007614.3	Beta-catenin
Gene ( <i>Mus musculus</i> )	Apc	GenBank	NM_001360980.1	Adenomatous polyposis coli
Strain, strain background ( <i>Mus musculus</i> )	Arid1a-lox	From Z. Wang's lab	<i>Arid1a</i> <sup>tm1.1Zhwa/J</sup>	<a href="https://www.jax.org/strain/027717">https://www.jax.org/strain/027717</a>
Strain, strain background ( <i>Mus musculus</i> )	Apc-lox	From Perret-Colnot's lab	<i>Apc</i> <sup>tm2.1Cip</sup>	<a href="https://www.infrafrontier.eu/search?keyword=EM:05566">https://www.infrafrontier.eu/search?keyword=EM:05566</a>
Strain, strain background ( <i>Mus musculus</i> )	Ttr-Cre-Tam	From Perret-Colnot's lab	Tg(Ttr-cre/Esr1*)1Vco	<a href="https://www.infrafrontier.eu/search?keyword=EM:01713">https://www.infrafrontier.eu/search?keyword=EM:01713</a>
Genetic reagent ( <i>Adenovirus 5</i> )	Ad-Cre	Université de Nantes, France	Ad5-CAG-Cre	<a href="https://umr1089.univ-nantes.fr/facilities-cores/cpv/translational-vector-core-2201753.kjsp?RH=1519296751975">https://umr1089.univ-nantes.fr/facilities-cores/cpv/translational-vector-core-2201753.kjsp?RH=1519296751975</a>
Cell line ( <i>Mus musculus</i> )	Mouse hepatoma	From Christine Perret's lab	Hepa 1-6 [Hepa1-6] (ATCC CRL-1830)	For transfection experiments
Antibody	anti-Arid1a (Rabbit monoclonal)	Abcam	Cat# 182560 [EPR13501]	IHC(1:1000), WB (1:2000)
Antibody	anti-Glul (GS) (Mouse monoclonal)	BD Biosciences	Cat# 610518, RRID:AB_397880	IHC(1:400), WB (1:5000)
Antibody	anti-HBB (Mouse monoclonal)	Proteintech	Cat# 16216-1-AP, RRID:AB_10598329	IHC(1:200), WB (1:2000)
Antibody	anti-HIF1 $\alpha$ (Rabbit polyclonal)	Novus	Cat# NB100-449, RRID:AB_10001045	WB nuclear extract (1:500)
Antibody	anti-HIF2 $\alpha$ (Rabbit polyclonal)	Novus	Cat# NB100-122, RRID:AB_10002593	WB nuclear extract (1:500)
Antibody	Anti-Tcf4 (Tcf7l2) (Mouse monoclonal)	Millipore	Cat# 05-511, RRID:AB_309772	ChIP: 3 $\mu$ g
Antibody	Anti-H3K27Ac (Rabbit polyclonal)	Active Motif	Cat# 39133, RRID:AB_2561016	ChIP: 3 $\mu$ g
Antibody	Anti-H3K27me3 (Rabbit polyclonal)	Active Motif	Cat# 39155, RRID:AB_2561020	ChIP: 3 $\mu$ g

Continued on next page

Continued

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Antibody	IgG (Mouse)	Thermo Fisher Scientific	Cat# 10400C, RRID:AB_2532980	ChIP: 3 µg
Antibody	Anti-CD71-FITC (Rat monoclonal)	BD Biosciences	Cat# 553266, RRID:AB_394743	FACS (1:100)
Antibody	Anti-Ter119-PE (rat monoclonal)	BD Biosciences	Cat# 553673, RRID:AB_394986	FACS (1:100)
Antibody	Anti-β-actin (mouse monoclonal)	Sigma-Aldrich	Cat# A5441, RRID:AB_476744	WB (1:10000)
Antibody	Anti-lamin A/C (rabbit polyclonal)	Cell Signaling Technology	Cat# 2032, RRID:AB_2136278	WB nuclear extract (1:500)
Antibody	IgG, HRP-conjugated (horse, anti-mouse)	Cell Signaling Technology	Cat# 7076, RRID:AB_330924	WB (1:2000)
Antibody	IgG, HRP-conjugated (goat, anti-rabbit)	Cell Signaling Technology	Cat# 7074, RRID:AB_2099233	WB (1:2000)
Antibody	IgG, biotinylated (goat, anti-rabbit)	Vector lab	Cat# BA-1000, RRID:AB_2313606	IHC (1:200)
Commercial assay or kit	MOM mouse on mouse	Vector Laboratories	Cat# BMK-2202, RRID:AB_2336833	Kit
Sequence-based reagent	18S	Thermo Fisher Scientific	Taqman Assay 4308329	qPCR primers
Sequence-based reagent	Glul	Thermo Fisher Scientific	Taqman Assay Mm00725701_si	qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Axin2	Thermo Fisher Scientific	Taqman Assay Mm00443610_m1	qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Arid1a (total)	Thermo Fisher Scientific	Taqman Assay Mm00473838_m1	qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Arid1a (not excised by Cre)	Thermo Fisher Scientific	Taqman Assay Mm00473841_m1	qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Apc (total)	Thermo Fisher Scientific	Taqman Assay Mm00545877_m1	qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Apc (not excised by Cre)	Thermo Fisher Scientific	Taqman Assay Mm01130462_m1	qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Epo	Thermo Fisher Scientific	Taqman Assay Mm01202755_m1	qPCR primers <i>Mus musculus</i>
Sequence-based reagent	18 s	Eurogentec	F_GTAACCCGT TGAACCCATT R_CCATCCAA TCGGTAGCG	SybrGreen qPCR primers
Sequence-based reagent	Angiopoietin-like 2 (Angptl2)	Eurogentec	F_CCGCAACAT GAACTCGAGAG R_GTGCTCCAGG TCCTTGTACT	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Carbonic anhydrase 9 (Car9)	Eurogentec	F_GACCTCGTG ATTCTCGGCTA R_GAGAAGGC CAAACACCAAGG	SybrGreen qPCR primers <i>Mus musculus</i>

Continued on next page

Continued

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Sequence-based reagent	Cyclin D1 (Ccnd1)	Eurogentec	F_AGAAGTGCG AAGAGGAGGTC R_TTCTCGGC AGTCAAGGGAAT	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Enolase 2, gamma neuronal (Eno2)	Eurogentec	F_TGGATTTC AGTCTCCCCT R_TCAGGTCAT CGCCCACTATC	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Erythropoietin receptor (Epo-r)	Eurogentec	F_ATGACTTTTCG TGAATCACCCT R_GGGCTCCG AAGAACTTCTGTG	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	FMS-like tyrosine kinase 1 (Flt1)	Eurogentec	F_AGAGGAGGA TGAGGGTGCT R_GGGAAGCTT CATCTGGGTCCA	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	GATA binding protein 1 (Gata1)	Eurogentec	F_TTCCCACTA CTGCTGCTACC R_GCGGCCTC TATTTCAAGCTC	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	GATA binding protein 2 (Gata2)	Eurogentec	F_GCCGGTTCT GTCCATTCATC R_ATGGCAGCA GTCTCTTCCAT	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Inhibin beta-B (Inhbb)	Eurogentec	F_GTACCTGAAA CTGCTCCCCT R_ATGGCCTC TGTGATGGGAAA	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Potassium channel tetramer domain contain. 11 (Kctd11)	Eurogentec	F_TGACTTCTAC CAGATCCGGC R_TCAGGGTCAG TGCAGAAGAG	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Kinase insert domain protein receptor (Kdr)	Eurogentec	F_AGAAGATGC CCATGACCCAA R_TCACCCATC CTCAACACACA	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Nuclear factor, erythroid derived 2 (Nfe2)	Eurogentec	F_GATGTCCCGA ACTAGAGCCA R_ACACCCTTG GCCTTAGAGTC	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Platelet derived growth factor receptor, alpha polypeptide (Pdgfra)	Eurogentec	F_ACAGCTCAC AGACTTCGGAA R_AGAAGATGA TACCCGGAGCG	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Phosphoglycerate kinase 1 (Pkg1)	Eurogentec	F_TGGCACCAG GAACCCTTAAA R_AGCTCAGCC TTTACAGCTCA	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Placenta-specific 8 (Plac8)	Eurogentec	F_TGATTGCTT CAGTGACTGCG R_GTTTCATGGC TCTCCTCTGT	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Protein tyrosine phosphatase, receptor type, B (Ptpnb)	Eurogentec	F_TGGACCCTG GGATCTAAGGA R_GTGGTCACT GCAAGCTTCAA	SybrGreen qPCR primers <i>Mus musculus</i>

Continued on next page

Continued

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Sequence-based reagent	Member RAS oncogene family (Rab42)	Eurogentec	F_GGCGTTCTG TTGGTCTTTGA R_GCAAGTTCCT CTGCTTCCTG	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Vascular endothelial growth factor A (Vegfa)	Eurogentec	F_GCTGTAACGAT GAAGCCCTG R_CGCTCCAGG ATTTAAACCGG	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	Zinc finger protein, multitype 1 (Zfp1)	Eurogentec	F_CCTTGAGATG GCGTTCACAG R_CCTGCTCTA CTACTGTGCCA	SybrGreen qPCR primers <i>Mus musculus</i>
Sequence-based reagent	AT-rich interaction domain 1A (ARID1A)	Eurogentec	F_AAGCCACCAA CTCCAGCATCCA R_CGCTTCTGG AATGTGGAGTCAC	SybrGreen qPCR primers ( <i>Homo sapiens</i> )
Sequence-based reagent	Adenomatous polyposis coli (APC)	Eurogentec	F_CACACTTCCAA CTTCTCGCAACG R_AGGCTGCAT GAGAGCACTTGTG	SybrGreen qPCR primers ( <i>Homo sapiens</i> )
Sequence-based reagent	Erythropoietin (EPO)	Eurogentec	F_GCATGTGGAT AAAGCCGTCAGTG R_GAGTTTGCGGA AAGTGTCAGCAG	SybrGreen qPCR primers ( <i>Homo sapiens</i> )
Sequence-based reagent	DOS7-binding site (Control)	Eurogentec	F_GGGGTAGG AACCAATGAAA R_TTTCATTGG TTCCTACCCC	EMSA probe <i>Mus musculus</i>
Sequence-based reagent	HNF4-responsive element (DR2)	Eurogentec	F_GCCCGGCTGACC TCTTGACCCCTCT GGGCTTGAG R_CTAAGCCCAGA GGGGTCAAGAG GTCAGCCGGGC	EMSA probe <i>Mus musculus</i>
Sequence-based reagent	Wnt-reponsive element	Eurogentec	F_CATCCCCCT TTGATCTTACC R_GGTAAGATC AAAGGGGGATG	EMSA probe
Sequence-based reagent	Negative control region	Eurogentec	F_ACACACCTT GAATCCCGT R_CCCAGCTA GAATGAACAAG	qPCR primers for ChIP and ATAC
Sequence-based reagent	Hepatic Epo 3' enhancer	Eurogentec	F_CTGTACCTCA CCCCATCTGGTC R_CCCAGCTCA CTCAGCACTTGTCC	qPCR primers for ChIP and ATAC
Sequence-based reagent	EPO-enh-5' (1)	Eurogentec	F_GGCAACAGC TGAAATCACCAA R_TCCCAGATC TGATGCCTTG	qPCR primers for ATAC
Sequence-based reagent	EPO-enhHIF (2)	Eurogentec	F_CTGTACCTC ACCCATCTGG R_CAGAGGG GTCAAGAGGTCAG	qPCR primers for ChIP and ATAC
Sequence-based reagent	EPO-enhHnf4 (3)	Eurogentec	F_GCAAGGCAT CAGATCTGGGA R_AGACAGCCT TGAATGGAGCC	qPCR primers for ChIP and ATAC

## Animals

Mice carrying two floxed alleles in the 14th exon of the *Apc* gene (generated in our laboratory [Colnot et al., 2004]) or the 8th exon of the *Arid1a* gene (created by the Zhong Wang laboratory [Gao et al., 2008]), were interbred with TTR-Cre<sup>Tam</sup> mice (Tannour-Louet et al., 2002), resulting in *Apc*<sup>flox/+</sup>/TTR-Cre<sup>Tam</sup> or *Arid1a*<sup>flox/+</sup>/TTR-Cre<sup>Tam</sup> mice. For focal genetic inactivation, 8-week-old *Apc*<sup>flox/flox</sup> and *Arid1a*<sup>flox/flox</sup> male mice were injected intravenously with  $0.5 \times 10^9$  infectious particles of Ad5-CAG-cre (AdCre) adenovirus as described (Colnot et al., 2004). Mice with hepato-specific and AdCre-mediated inactivation of *Apc* and/or *Arid1a* in single hepatocytes are referred to as [*Apc-Arid1a*]<sup>ko-focal</sup>, [*Apc*]<sup>ko-focal</sup>, and [*Arid1a*]<sup>ko-focal</sup> mice. The development of tumors and peliosis were followed monthly by 2D-ultrasound (Vevo 770, Visualsonics). For panlobular genetic inactivation, 8-week-old *Apc*<sup>flox/flox</sup>/Ttr-Cre<sup>Tam</sup> and *Arid1a*<sup>flox/flox</sup>/Ttr-Cre<sup>Tam</sup> male mice were given a tamoxifen diet (M-Z, low phytoestrogen +1000 mg/kg TAM citrate, SSNIFF, Soest, Germany) for 4 days. These mice are referred to as [*Apc-Arid1a*]<sup>ko-TOTAL</sup>, [*Apc*]<sup>ko-TOTAL</sup>, and [*Arid1a*]<sup>ko-TOTAL</sup> mice.

Mice were housed under conventional conditions and all reported animal procedures were carried out according to French government regulations (Ethics Committee of Descartes University, Paris). The animal welfare assurance number is APAFIS#14472.

## Immunohistochemistry and in situ hybridization experiments

After sacrifice, livers were harvested, fixed overnight in 4% formalin buffer, and embedded in paraffin. FFPE liver sections were treated as previously described for immunocytochemistry and HE stainings (de La Coste et al., 1998). Antibodies used are listed in the Key Resources Table.

RNA in situ hybridization was done on freshly cut 7  $\mu$ m FFPE liver or kidney sections using the RNAScope 2.5 HD Duplex Kit, with HybEZ II hybridization system, following the manufacturer's instructions (Advanced Cell Diagnostics). The following RNAScope probes were used: Epo (Mm-Epo-C2, Cat. 315501-C2, NM\_007942.2, region 39–685), Axin2 (Mm-Axin2, Cat. 400331, NM\_015732.4, region 330–1287), DapB (negative control, Cat. 320751, CP015375.1, region 2252107–2252555), Polr2a (positive control, Mm-Polr2a, Cat. 320761, NM\_001291068.1, region 3212–4088).

## Hematological analysis and red blood cell counts

Hematological parameters were measured using a CoulterMAXM automatic analyzer (Beckman Coulter) as previously described (Mastrogiannaki et al., 2009).

## Plasma collection and ELISA for erythropoietin

At sacrifice, peripheral blood was collected from the inferior vena cava with a heparinized needle (Sigma Aldrich – H3393-50KU). Plasma samples were stored at  $-80^{\circ}\text{C}$ . Plasma EPO protein levels were determined using a Quantikine mouse EPO enzyme-linked immunosorbent assay kit (R and D systems – MEP00B), according to the manufacturer's instructions.

## Treatment with anti-erythropoietin blocking serum

One-year-old [*Apc-Arid1a*]<sup>ko-focal</sup> and control mice were injected with anti-erythropoietin rabbit serum, as previously described (Mastrogiannaki et al., 2012), with minor modifications: injections were performed for 7 consecutive days and mice were sacrificed 18 hr after the last injection. The dose injected was described as able to neutralize a 10-fold excess of circulating erythropoietin (Mastrogiannaki et al., 2012). At sacrifice, liver and spleen were collected for immunohistochemistry and cytometry analysis.

## Hepatocyte isolation and cell culture

Livers from 3-month-old mice were perfused 7 days after the beginning of the tamoxifen diet (1000 mg/kg) with collagenase. The liver cell suspension was collected, and hepatocytes were separated from NPCs by centrifugation for 2 min at 48 g as previously described (Anson et al., 2012). The supernatant containing the NPCs was collected and centrifuged for 10 min at 440 g. Hepatocytes were plated as previously described (Gougelet et al., 2014; Torre et al., 2011; Guidotti et al., 2003). Hepa1-6 hepatoma cell line was a gift from C. Perret's lab, authenticated by its CTNNB1 mutation, assessed by Sanger sequencing. It was tested negative for mycoplasma contamination.

Cells were plated at  $3 \times 10^5$  cells per well, in six-well plates, in DMEM solution supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and fungizone.

Cryopreserved human hepatocytes were obtained from Triangle Research Laboratory (Lonza). They were seeded at confluency ( $2.1 \times 10^5$  cell/cm<sup>2</sup>) and cultured in a humidified 5% CO<sub>2</sub> atmosphere at 37°C in hepatocyte growth medium (HGM: WME medium supplemented with 5 µg/ml insulin, 0.1 µM hydrocortisone, 10 µg/ml transferrin, 250 µg/ml ascorbic acid, 3.75 mg/ml fatty-acid-free bovine serum albumin, 2 mM glutamine, penicillin and streptomycin).

### Cell transfection, stimulation, and luciferase assays

Primary murine hepatocytes were transfected with 20 nM small-interfering RNA (siRNA) directed against *Arid1a* (Qiagen SI00230405) or control siRNA (Dharmacon D-001210-01-05) in the presence of Lipofectamine 2000 (Thermo Fisher Scientific). The next day, cells were stimulated, or not, with 100 ng/ml recombinant mouse Wnt3a (1324-WN) and 100 ng/ml recombinant mouse R-Spondin 3 Protein (4120-RS) (R and D Systems). Molecular analyses were performed 48 hr after transfection or stimulation.

HEPA 1.6 cells were transfected for 24 and 48 hr with 20 nM siRNA directed against *Arid1a* or  $\beta$ -catenin (QiagenSI00942039) or control siRNA. Molecular analyses were performed 72 hr after the first transfection.

Adherent primary human hepatocytes were transfected with 20 nM non-targeting siRNA or siRNAs specific for *APC* (Dharmacon, Lafayette, CO) or *ARID1A* (Qiagen 1027416) at day 1 and day 3 after seeding, using Lipofectamine RNAiMAX (Life Technologies, Carlsbad, CA).

For luciferase assay, primary mouse hepatocytes were transfected using Lipofectamine 2000 (ThermoFisher Scientific) with 1 µg of a luciferase reporter driven by erythropoietin 3' enhancer region (Epo-3'E, 50 nucleotides) (Huang *et al.*, 1996), and/or 500 ng of a Renilla vector (Promega, Madison, WI). Luciferase activity was measured 48 hr after transfection with the Dual-Luc kit, according to manufacturer's protocols (Promega).

### Isolation of peliosis-like areas from paraffin-embedded (FFPE) tissue sections and Affymetrix microarrays

Healthy and peliosis-like areas were isolated from 15 to 20 paraffin sections (10 µm) using a small needle under a binocular magnifying glass. After deparaffinization, FFPE tissues were lysed for 24 hr in tissue lysis with proteinase K (Qiagen) at 60°C. Microarray transcriptomic analysis from paraffin-embedded (FFPE) tissue sections was performed on the MTA-31461 chip. Gene set enrichment analysis (GSEA) was performed using the Java tool application available at the Broad Institute (Cambridge, MA, USA). The analysis was performed using Hallmark gene data sets.

### RNA extraction and quantitative RT-PCR

Total RNA was extracted with Trizol reagent (Thermo Fisher Scientific) as previously described (Gougelet *et al.*, 2016). Reverse transcription was performed from 100 ng RNA with a cDNA synthesis kit from Thermo Scientific (K1642). The Taqman assays (Thermo Fisher Scientific) and the sequences of PCR primers (Eurogentec) for SybrGreen assays are described in the Key Resources Table. qPCR was performed in duplicate on a LightCycler480 apparatus and the results, analyzed by the  $\Delta\Delta C_t$  technique, expressed relative to those for 18S RNA.

### Calculation of gene inactivation efficiencies

*Arid1a* and *Apc* mRNAs were analyzed by RT-qPCR. For each gene, we used two distinct Taqman assays: (1) One contained two primers both located in undeleted regions. It allowed to detect both wild type and inactivated genes, so the relative mRNA expression of 'TOTAL' gene; (2) In the other, one primer was located in the deleted region. Thus, this Taqman assay allowed to detect and amplify only the 'non excised' gene. We quantified the percentage of inactivation as follows: % of gene inactivation =  $(1 - (\text{mRNA expression of TOTAL gene expression} / \text{mRNA expression of undeleted gene expression})) \times 100$ .

## Protein extracts and western blotting

Livers were lysed mechanically in RIPA buffer (Sigma Aldrich – R0278-50ml) with protease inhibitors (Roche - 11697498001), and boiled in Laemmli sample buffer (Sigma Aldrich – S3401-1VL). 50 µg of protein per lane were run on 8% polyacrylamide gels. The resulting protein bands were electrotransferred onto a 0.2 µm nitrocellulose membrane (Biorad 162–0112), which was then blocked with 5% blocking reagent (Biorad 170–6404) in TBS/Tween 0.1% for 1 hr at RT, probed overnight with the primary antibody, and then incubated with IgG HRP-conjugated secondary antibody for detection with the Clarity ECL substrate (Biorad 70–5061).

To analyze nuclear protein extracts, livers were lysed in Hepes 10 mM pH7.9, KCl 10 mM, EDTA 0.1 mM, EGTA 0.1 mM, DTT 1 mM, AEBSF 0.5 mM. Then, after addition of 12.5 µl of NP40 20% and centrifugation, the pellet was resuspended in Hepes 20 mM pH7.9, NaCl 400 mM, EDTA 1 mM, EGTA 1 mM, DTT 1 mM, AEBSF 1 mM, PIC1X, Glycerol 5%, and the supernatants boiled in Laemmli. We next ran 70 µg of protein per lane on Bolt 4–12% Bis-TrisPlus Gels (Thermo Fisher, NW04125BOX). Detection was performed by using Super Signal West Dura ECL system (Thermo Fisher, 34076).

## Electrophoretic mobility shift assay (EMSA)

Nuclear proteins preparation and LXR electromobility shift assay (EMSA) were performed as previously described (Bobard *et al.*, 2005). The probes are listed in the Key Resources Table. The HRE element from the Epo-3'E is constituted from two direct repeats of GG/AGTCA sequences with a spacing of two nucleotides (thereafter called DR2).

## Flow cytometry and c-forming unit-erythroid (CFU-E) assays

Primary mouse bone marrow, spleen cells, and NPC liver cells were harvested from [*Apc-Arid1a*]<sup>ko-focal</sup> mice and their wild-type littermates and erythroid cell populations were identified and analysed using CD71/TER119 flow-cytometric assay. Staining was performed in a 96-well plate and samples (5.10<sup>4</sup> cells) were washed once in PBS, 0.4% BSA, 0.1% Sodium Azide, sample staining volume was 50 µl of mix primary-antibody solution, to a final concentration 1.0 × 10<sup>6</sup> cells/ml. Primary antibody staining mix were prepared for CD71-FITC and Ter119-PE. Unstained cells, Isotype Ig and single stained cells were used as control and to define boundaries between negative and positive cell labelling. After incubation in the primary antibody stain, two washes were performed by adding 200 µl of staining buffer to each sample.

For CFU-E formation, we plated in duplicate 2 × 10<sup>5</sup> bone marrow cells or 2 × 10<sup>6</sup> splenic/NPC liver cells in MethoCult M3234 (StemCell Technologies), supplemented, or not, with 2 U EPO. The number of CFU-E colonies was counted after 3 days.

## Chromatin immunoprecipitation (ChIP) and ATAC-qPCR assays

ChIP assay was previously described for hepatocytes isolated after collagenase perfusion in Gougelet *et al.*, 2014. Chromatin was immunoprecipitated using 3 µg antibody preabsorbed onto 60 µl protein G agarose (Thermo Fisher Scientific – 10004D). Bindings were assessed on the Axin2 intronic enhancer and hepatic Epo enhancer, relative to that of the immunoglobulin isotype control, by Taqman assay and SYBR green technology, respectively with the following oligonucleotides (Eurogentec): negative control region and hepatic Epo enhancer. Enrichment by ChIP was assessed relative to the input DNA and normalized to the level of the negative controls.

ATAC-qPCR assays were done using omni-ATAC as described in Corces *et al.*, 2017, on frozen liver samples after isolation of nuclei. Then, 50,000 nuclei were used for transposition for 30 min in 50 µl reaction mix containing 2.5 µl transposase (Illumina kit #FC-121–103), digitonin and tween 20 at 0.1%. After transposition, the following steps were done according to the initial protocol (Buenroostro *et al.*, 2015). The qPCR step was similar to ChIP experiments.

## Statistics

We assessed statistical significances with GraphPad Prism six software. The data represent the mean ± SEM and p values were calculated by two-tailed unpaired Student's t-test, one-way ANOVA, or two-way ANOVA as specified in the figure legends. p<0.05 was considered statistically significant and exact p-values are mentioned unless \*\*\*\*p<0.0001. Each quantitative experiment was repeated

at least three times. We considered biological replicates as those animals or tissues subjected to the same experimental test, and technical replicates as individual samples or tissues subjected to the same analysis.

## Acknowledgements

This work was supported by the French National League against Cancer (LNCC), by the IDEX 'Epiliv-can', by the Institut National du Cancer 'Epigenetics and Liver Cancer', and by the Plan-Cancer Programme « CHROMA-LIV ». RR got fellowships from the French Laboratory of Excellence program 'Who am I ?' (no ANR-11-LABX-0071 included in the Investments for the Future program n° ANR-11-IDEX-0005-01), and the French Foundation for Cancer Research (ARC). We are thankful to Dr C Peyssonnaud team for discussions on erythropoietin expression, and help to measure hematological blood parameters. We are thankful to Dr P Mayeux, JC Deschemin and Dr E Huang for the gift of anti-EPO blocking serum, DFO and EpoE-LUC plasmid, respectively. We wish to thank the animal housing facility at Cochin Institute, and the 'GENOM'IC' facility for transcriptomic data generation and analysis. We are very grateful to Dr C Desbois-Mouthon, Dr S Vaulont and Pr J Weitzman for critical reading of the manuscript, and to Pr J Weitzman, Pr J Zucman-Rossi and Dr C Desdouets for helpful discussions.

## Additional information

### Funding

Funder	Grant reference number	Author
Institut National Du Cancer	Epigenetics and Liver Cancer	Rozenn Riou Angélique Gougelet Cécile Godard Julien Calderaro Sabine Colnot
Ligue Contre le Cancer	Equipe Labellisée	Rozenn Riou Angélique Gougelet Cécile Godard Sabine Colnot
Agence Nationale de la Recherche	Labex "Who Am I"	Rozenn Riou Angélique Gougelet Cécile Godard Sabine Colnot
Institut National Du Cancer	Chromaliv	Rozenn Riou Angélique Gougelet Cécile Godard Sabine Colnot
Agence Nationale de la Recherche	I dex "EpilivCan"	Rozenn Riou Angélique Gougelet Cécile Godard Sabine Colnot

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

### Author contributions

Rozenn Riou, Conceptualization, Formal analysis, Validation, Investigation, Visualization; Meriem Ladli, Validation, Investigation, Visualization; Sabine Gerbal-Chaloin, Formal analysis, Supervision, Validation, Visualization; Pascale Bossard, Formal analysis, Supervision, Validation, Investigation, Visualization; Angélique Gougelet, Julien Calderaro, Formal analysis, Investigation; Cécile Godard, Isabelle Lagoutte, Franck Lager, Investigation; Robin Loesch, Alexandre Dos Santos, Investigation, Involved in the revision process; Zhong Wang, Resources; Frédérique Verdier, Formal analysis, Supervision, Validation, Investigation, Methodology; Sabine Colnot, Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology

**Author ORCIDs**Zhong Wang  <http://orcid.org/0000-0002-8720-4609>Sabine Colnot  <https://orcid.org/0000-0002-3949-9107>**Ethics**

Animal experimentation: This study was performed in strict accordance with the French government regulations. All of the animals were handled according to approved institutional animal care and use committee (Ethics Committee of Descartes University, Paris). The protocol was approved by the Ethics Committee of Descartes University, Paris (permit number APAFIS#14472). Every effort was made to minimize suffering.

**Decision letter and Author response**Decision letter <https://doi.org/10.7554/eLife.53550.sa1>Author response <https://doi.org/10.7554/eLife.53550.sa2>**Additional files****Supplementary files**

- Transparent reporting form

**Data availability**

Microarrays have been deposited in GEO database (GSE134553) and are publicly available. All data generated or analysed during this study are included in the manuscript and supporting files. Source data excel files have been provided for Figures 1, 2, 3, 4, 5, 7, 8, 1S1, 1S3, 3S1, 5S1, 5S2, 7S1.

The following dataset was generated:

Author(s)	Year	Dataset title	Dataset URL	Database and Identifier
Colnot S, Riou R	2020	Expression data from isolated areas from [Apc-Arid1a]ko-focal liver tissues after FFPE treatment	<a href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134553">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134553</a>	NCBI Gene Expression Omnibus, GSE134553

**References**

- Allredge JK, Eskander RN. 2017. EZH2 inhibition in *ARID1A* mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers. *Gynecologic Oncology Research and Practice* **4**:17. DOI: <https://doi.org/10.1186/s40661-017-0052-y>, PMID: 29093822
- Anson M, Crain-Denoyelle AM, Baud V, Chereau F, Gougelet A, Terris B, Yamagoe S, Colnot S, Viguier M, Perret C, Couty JP. 2012. Oncogenic  $\beta$ -catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. *Journal of Clinical Investigation* **122**:586–599. DOI: <https://doi.org/10.1172/JCI43937>, PMID: 22251704
- Bahar Halpern K, Tanami S, Landen S, Chapal M, Szlak L, Hutzler A, Nizhberg A, Itzkovitz S. 2015. Bursty gene expression in the intact mammalian liver. *Molecular Cell* **58**:147–156. DOI: <https://doi.org/10.1016/j.molcel.2015.01.027>, PMID: 25728770
- Barker N, Hurlstone A, Musisi H, Miles A, Bienz M, Clevers H. 2001. The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. *The EMBO Journal* **20**:4935–4943. DOI: <https://doi.org/10.1093/emboj/20.17.4935>, PMID: 11532957
- Benhamouche S, Decaens T, Godard C, Chambrey R, Rickman DS, Moinard C, Vasseur-Cognet M, Kuo CJ, Kahn A, Perret C, Colnot S. 2006. Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. *Developmental Cell* **10**:759–770. DOI: <https://doi.org/10.1016/j.devcel.2006.03.015>, PMID: 16740478
- Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih I, Conejo-Garcia JR, Speicher DW, Zhang R. 2015. Synthetic lethality by targeting EZH2 methyltransferase activity in *ARID1A*-mutated cancers. *Nature Medicine* **21**:231–238. DOI: <https://doi.org/10.1038/nm.3799>, PMID: 25686104
- Bobard A, Hainault I, Ferré P, Foufelle F, Bossard P. 2005. Differential regulation of sterol regulatory element-binding protein 1c transcriptional activity by insulin and liver X receptor during liver development. *Journal of Biological Chemistry* **280**:199–206. DOI: <https://doi.org/10.1074/jbc.M406522200>, PMID: 15509573

- Buenrostro JD**, Wu B, Chang HY, Greenleaf WJ. 2015. ATAC-seq: a method for assaying chromatin accessibility Genome-Wide. *Current Protocols in Molecular Biology* **109**:21 29 21–21 29 29. DOI: <https://doi.org/10.1002/0471142727.mb2129s109>, PMID: 25559105
- Bunn HF**. 2013. Erythropoietin. *Cold Spring Harbor Perspectives in Medicine* **3**:a011619. DOI: <https://doi.org/10.1101/cshperspect.a011619>, PMID: 23457296
- Cavard C**, Colnot S, Audard V, Benhamouche S, Finzi L, Torre C, Grimber G, Godard C, Terris B, Perret C. 2008. Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. *Future Oncology* **4**: 647–660. DOI: <https://doi.org/10.2217/14796694.4.5.647>, PMID: 18922122
- Colnot S**, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, Giovannini M, Perret C. 2004. Liver-targeted disruption of apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. *PNAS* **101**:17216–17221. DOI: <https://doi.org/10.1073/pnas.0404761101>, PMID: 15563600
- Colnot S**. 2016. Focusing on beta-catenin activating mutations to refine liver tumor profiling. *Hepatology* **64**: 1850–1852. DOI: <https://doi.org/10.1002/hep.28761>, PMID: 27515244
- Corces MR**, Trevino AE, Hamilton EG, Greenside PG, Sinnott-Armstrong NA, Vesuna S, Satpathy AT, Rubin AJ, Montine KS, Wu B, Kathiria A, Cho SW, Mumbach MR, Carter AC, Kasowski M, Orloff LA, Risca VI, Kundaje A, Khavari PA, Montine TJ, et al. 2017. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. *Nature Methods* **14**:959–962. DOI: <https://doi.org/10.1038/nmeth.4396>, PMID: 28846090
- de La Coste A**, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C. 1998. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. *PNAS* **95**:8847–8851. DOI: <https://doi.org/10.1073/pnas.95.15.8847>, PMID: 9671767
- de la Serna IL**, Ohkawa Y, Imbalzano AN. 2006. Chromatin remodelling in mammalian differentiation: lessons from ATP-dependent remodelers. *Nature Reviews Genetics* **7**:461–473. DOI: <https://doi.org/10.1038/nrg1882>, PMID: 16708073
- Eckey M**, Kuphal S, Straub T, Rümmele P, Kremmer E, Bosserhoff AK, Becker PB. 2012. Nucleosome remodeler SNF2L suppresses cell proliferation and migration and attenuates wnt signaling. *Molecular and Cellular Biology* **32**:2359–2371. DOI: <https://doi.org/10.1128/MCB.06619-11>, PMID: 22508985
- Gao X**, Tate P, Hu P, Tjian R, Skarnes WC, Wang Z. 2008. ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. *PNAS* **105**:6656–6661. DOI: <https://doi.org/10.1073/pnas.0801802105>, PMID: 18448678
- Gougelet A**, Torre C, Veber P, Sartor C, Bachelot L, Denechaud PD, Godard C, Moldes M, Burnol AF, Dubuquoy C, Terris B, Guillonneau F, Ye T, Schwarz M, Braeuning A, Perret C, Colnot S. 2014. T-cell factor 4 and  $\beta$ -catenin chromatin occupancies pattern zonal liver metabolism in mice. *Hepatology* **59**:2344–2357. DOI: <https://doi.org/10.1002/hep.26924>, PMID: 24214913
- Gougelet A**, Sartor C, Bachelot L, Godard C, Marchiol C, Renault G, Tores F, Nitschke P, Cavard C, Terris B, Perret C, Colnot S. 2016. Antitumour activity of an inhibitor of miR-34a in liver Cancer with  $\beta$ -catenin-mutations. *Gut* **65**:1024–1034. DOI: <https://doi.org/10.1136/gutjnl-2014-308969>, PMID: 25792709
- Gougelet A**, Sartor C, Senni N, Calderaro J, Fartoux L, Lequoy M, Wendum D, Talbot JN, Prignon A, Chalaye J, Imbeaud S, Zucman-Rossi J, Tordjmann T, Godard C, Bossard P, Rosmorduc O, Amaddeo G, Colnot S. 2019. Hepatocellular carcinomas with mutational activation of Beta-Catenin require choline and can be detected by positron emission tomography. *Gastroenterology* **157**:807–822. DOI: <https://doi.org/10.1053/j.gastro.2019.05.069>, PMID: 31194980
- Guichard C**, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo F, Zucman-Rossi J. 2012. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. *Nature Genetics* **44**:694–698. DOI: <https://doi.org/10.1038/ng.2256>, PMID: 22561517
- Guidotti JE**, Brégerie O, Robert A, Debey P, Brechot C, Desdouets C. 2003. Liver cell polyploidization: a pivotal role for binuclear hepatocytes. *Journal of Biological Chemistry* **278**:19095–19101. DOI: <https://doi.org/10.1074/jbc.M300982200>, PMID: 12626502
- Hoshimoto S**, Morise Z, Suzuki K, Tanahashi Y, Ikeda M, Kagawa T, Mizoguchi Y, Sugioka A. 2009. Hepatocellular carcinoma with extensive peliotic change. *Journal of Hepato-Biliary-Pancreatic Surgery* **16**:566–570. DOI: <https://doi.org/10.1007/s00534-008-0035-9>, PMID: 19183829
- Huang LE**, Arany Z, Livingston DM, Bunn HF. 1996. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. *Journal of Biological Chemistry* **271**:32253–32259. DOI: <https://doi.org/10.1074/jbc.271.50.32253>, PMID: 8943284
- Jelkmann W**. 2007. Erythropoietin after a century of research: younger than ever. *European Journal of Haematology* **78**:183–205. DOI: <https://doi.org/10.1111/j.1600-0609.2007.00818.x>, PMID: 17253966
- Kadoch C**, Copeland RA, Keilhack H. 2016. PRC2 and SWI/SNF chromatin remodeling complexes in health and disease. *Biochemistry* **55**:1600–1614. DOI: <https://doi.org/10.1021/acs.biochem.5b01191>, PMID: 26836503
- Kaidi A**, Williams AC, Paraskeva C. 2007. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. *Nature Cell Biology* **9**:210–217. DOI: <https://doi.org/10.1038/ncb1534>, PMID: 17220880
- Ke S**, Chen S, Dong Z, Hong CS, Zhang Q, Tang L, Yang P, Zhai J, Yan H, Shen F, Zhuang Z, Wen W, Wang H. 2017. Erythrocytosis in hepatocellular carcinoma portends poor prognosis by respiratory dysfunction secondary to mitochondrial DNA mutations. *Hepatology* **65**:134–151. DOI: <https://doi.org/10.1002/hep.28889>, PMID: 27774607

- Kimáková P**, Solár P, Solárová Z, Komel R, Debeljak N. 2017. Erythropoietin and its angiogenic activity. *International Journal of Molecular Sciences* **18**:1519. DOI: <https://doi.org/10.3390/ijms18071519>, PMID: 28703764
- Kular D**, Macdougall IC. 2019. HIF stabilizers in the management of renal Anemia: from bench to bedside to pediatrics. *Pediatric Nephrology* **34**:365–378. DOI: <https://doi.org/10.1007/s00467-017-3849-3>, PMID: 29569190
- Lacombe C**, Da Silva JL, Bruneval P, Fournier JG, Wendling F, Casadevall N, Camilleri JP, Bariety J, Varet B, Tambourin P. 1988. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. *Journal of Clinical Investigation* **81**:620–623. DOI: <https://doi.org/10.1172/JCI113363>, PMID: 3339134
- Mastrogiannaki M**, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaud C. 2009. HIF-2 $\alpha$ , but not HIF-1 $\alpha$ , promotes iron absorption in mice. *Journal of Clinical Investigation* **119**:1159–1166. DOI: <https://doi.org/10.1172/JCI38499>, PMID: 19352007
- Mastrogiannaki M**, Matak P, Mathieu JR, Delga S, Mayeux P, Vaulont S, Peyssonnaud C. 2012. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. *Haematologica* **97**:827–834. DOI: <https://doi.org/10.3324/haematol.2011.056119>, PMID: 22207682
- Mathur R**, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, Park PJ, Shivdasani RA, Roberts CW. 2017. ARID1A loss impairs enhancer-mediated gene regulation and drives Colon cancer in mice. *Nature Genetics* **49**:296–302. DOI: <https://doi.org/10.1038/ng.3744>, PMID: 27941798
- Matsuyama M**, Yamazaki O, Horii K, Higaki I, Kawai S, Mikami S, Higashino M, Oka H, Nakai T, Inoue T. 2000. Erythrocytosis caused by an erythropoietin-producing hepatocellular carcinoma. *Journal of Surgical Oncology* **75**:197–202. DOI: [https://doi.org/10.1002/1096-9098\(200011\)75:3<197::AID-JSO8>3.0.CO;2-I](https://doi.org/10.1002/1096-9098(200011)75:3<197::AID-JSO8>3.0.CO;2-I), PMID: 11088052
- Minamishima YA**, Kaelin WG. 2010. Reactivation of hepatic EPO synthesis in mice after PHD loss. *Science* **329**:407. DOI: <https://doi.org/10.1126/science.1192811>, PMID: 20651146
- Monga SP**. 2015.  $\beta$ -Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. *Gastroenterology* **148**:1294–1310. DOI: <https://doi.org/10.1053/j.gastro.2015.02.056>, PMID: 25747274
- Mosimann C**, Hausmann G, Basler K. 2009. Beta-catenin hits chromatin: regulation of wnt target gene activation. *Nature Reviews Molecular Cell Biology* **10**:276–286. DOI: <https://doi.org/10.1038/nrm2654>, PMID: 19305417
- Nagl NG**, Patsialou A, Haines DS, Dallas PB, Beck GR, Moran E. 2005. The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. *Cancer Research* **65**:9236–9244. DOI: <https://doi.org/10.1158/0008-5472.CAN-05-1225>, PMID: 16230384
- Nogueira-Pedro A**, dos Santos GG, Oliveira DC, Hastreiter AA, Fock RA. 2016. Erythropoiesis in vertebrates: from ontogeny to clinical relevance. *Frontiers in Bioscience : A Journal and Virtual Library* **8**:100–112.
- Perry JM**, Harandi OF, Porayette P, Hegde S, Kannan AK, Paulson RF. 2009. Maintenance of the BMP4-dependent stress erythropoiesis pathway in the murine spleen requires hedgehog signaling. *Blood* **113**:911–918. DOI: <https://doi.org/10.1182/blood-2008-03-147892>, PMID: 18927434
- Planas-Paz L**, Orsini V, Boulter L, Calabrese D, Pikiokle M, Nigsch F, Xie Y, Roma G, Donovan A, Marti P, Beckmann N, Dill MT, Carbone W, Bergling S, Isken A, Mueller M, Kinzel B, Yang Y, Mao X, Nicholson TB, et al. 2016. The RSPO-LGR4/5-ZNRF3/RNF43 module controls liver zonation and size. *Nature Cell Biology* **18**:467–479. DOI: <https://doi.org/10.1038/ncb3337>, PMID: 27088858
- Rebouissou S**, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, Nault JC, Couchy G, Laurent A, Balabaud C, Bioulac-Sage P, Zucman-Rossi J. 2016. Genotype-phenotype correlation of CTNNB1 mutations reveals different  $\beta$ -catenin activity associated with liver tumor progression. *Hepatology* **64**:2047–2061. DOI: <https://doi.org/10.1002/hep.28638>, PMID: 27177928
- Ruschitzka FT**, Wenger RH, Stallmach T, Quaschnig T, de Wit C, Wagner K, Labugger R, Kelm M, Noll G, Rüllicke T, Shaw S, Lindberg RL, Rodenwaldt B, Lutz H, Bauer C, Lüscher TF, Gassmann M. 2000. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. *PNAS* **97**:11609–11613. DOI: <https://doi.org/10.1073/pnas.97.21.11609>, PMID: 11027359
- Semenza GL**, Koury ST, Nejfelt MK, Gearhart JD, Antonarakis SE. 1991. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. *PNAS* **88**:8725–8729. DOI: <https://doi.org/10.1073/pnas.88.19.8725>, PMID: 1924331
- Sena JA**, Wang L, Hu CJ. 2013. BRG1 and BRM chromatin-remodeling complexes regulate the hypoxia response by acting as coactivators for a subset of hypoxia-inducible transcription factor target genes. *Molecular and Cellular Biology* **33**:3849–3863. DOI: <https://doi.org/10.1128/MCB.00731-13>, PMID: 23897427
- Senni N**, Savall M, Cabrerizo Granados D, Alves-Guerra MC, Sartor C, Lagoutte I, Gougelet A, Terris B, Gilgenkrantz H, Perret C, Colnot S, Bossard P. 2019.  $\beta$ -catenin-activated hepatocellular carcinomas are addicted to fatty acids. *Gut* **68**:322–334. DOI: <https://doi.org/10.1136/gutjnl-2017-315448>, PMID: 29650531
- Snipstad S**, Berg S, Mørch Ý, Bjørkøy A, Sulheim E, Hansen R, Grimstad I, van Wamel A, Maaland AF, Torp SH, Davies CL. 2017. Ultrasound improves the delivery and therapeutic effect of Nanoparticle-Stabilized Microbubbles in Breast Cancer Xenografts. *Ultrasound in Medicine & Biology* **43**:2651–2669. DOI: <https://doi.org/10.1016/j.ultrasmedbio.2017.06.029>, PMID: 28781149
- Song H**, Spichiger-Haeusermann C, Basler K. 2009. The ISWI-containing NURF complex regulates the output of the canonical wingless pathway. *EMBO Reports* **10**:1140–1146. DOI: <https://doi.org/10.1038/embor.2009.157>, PMID: 19713963
- Sun X**, Chuang JC, Kanchwala M, Wu L, Celen C, Li L, Liang H, Zhang S, Maples T, Nguyen LH, Wang SC, Signer RA, Sorouri M, Nassour I, Liu X, Xu J, Wu M, Zhao Y, Kuo YC, Wang Z, et al. 2016. Suppression of the SWI/SNF

- component Arid1a promotes mammalian regeneration. *Cell Stem Cell* **18**:456–466. DOI: <https://doi.org/10.1016/j.stem.2016.03.001>, PMID: 27044474
- Sun X, Wang SC, Wei Y, Luo X, Jia Y, Li L, Gopal P, Zhu M, Nassour I, Chuang JC, Maples T, Celen C, Nguyen LH, Wu L, Fu S, Li W, Hui L, Tian F, Ji Y, Zhang S, et al. 2018. Arid1a has Context-Dependent oncogenic and tumor suppressor functions in liver Cancer. *Cancer Cell* **33**:151–152. DOI: <https://doi.org/10.1016/j.ccell.2017.12.011>, PMID: 29316428
- Suzuki N, Obara N, Pan X, Watanabe M, Jishage K, Minegishi N, Yamamoto M. 2011. Specific contribution of the erythropoietin gene 3' enhancer to hepatic erythropoiesis after late embryonic stages. *Molecular and Cellular Biology* **31**:3896–3905. DOI: <https://doi.org/10.1128/MCB.05463-11>, PMID: 21746884
- Suzuki N. 2015. Erythropoietin gene expression: developmental-stage specificity, cell-type specificity, and hypoxia inducibility. *The Tohoku Journal of Experimental Medicine* **235**:233–240. DOI: <https://doi.org/10.1620/tjem.235.233>, PMID: 25786542
- Takeda K, Aguila HL, Parikh NS, Li X, Lamothe K, Duan LJ, Takeda H, Lee FS, Fong GH. 2008. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. *Blood* **111**:3229–3235. DOI: <https://doi.org/10.1182/blood-2007-09-114561>, PMID: 18056838
- Tannour-Louet M, Porteu A, Vaulont S, Kahn A, Vasseur-Cognet M. 2002. A tamoxifen-inducible chimeric cre recombinase specifically effective in the fetal and adult mouse liver. *Hepatology* **35**:1072–1081. DOI: <https://doi.org/10.1053/jhep.2002.33164>, PMID: 11981757
- Torre C, Benhamouche S, Mitchell C, Godard C, Veber P, Letourneur F, Cagnard N, Jacques S, Finzi L, Perret C, Colnot S. 2011. The transforming growth factor- $\alpha$  and cyclin D1 genes are direct targets of  $\beta$ -catenin signaling in hepatocyte proliferation. *Journal of Hepatology* **55**:86–95. DOI: <https://doi.org/10.1016/j.jhep.2010.10.021>, PMID: 21145869
- Torre LA, Siegel RL, Ward EM, Jemal A. 2016. Global Cancer incidence and mortality rates and trends—an update. *Cancer Epidemiology Biomarkers & Prevention* **25**:16–27. DOI: <https://doi.org/10.1158/1055-9965.EPI-15-0578>, PMID: 26667886
- Tsuchiya A, Kubota T, Takizawa K, Yamada K, Wakai T, Matsuda Y, Honma T, Watanabe M, Shirai Y, Maruyama H, Nomoto M, Aoyagi Y. 2009. Successful treatment in a case of massive hepatocellular carcinoma with paraneoplastic syndrome. *Case Reports in Gastroenterology* **3**:105–110. DOI: <https://doi.org/10.1159/000213480>, PMID: 20651974
- Valla DC, Cazals-Hatem D. 2018. Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts. *Virchows Archiv* **473**:3–13. DOI: <https://doi.org/10.1007/s00428-018-2331-3>, PMID: 29572606
- Vik A, Cui G, Isaksen V, Wik T, Hansen JB. 2009. Erythropoietin production by a hepatic adenoma in a patient with severe erythrocytosis. *Acta Haematologica* **121**:52–55. DOI: <https://doi.org/10.1159/000210556>, PMID: 19339771
- Wang F, Zhang R, Beischlag TV, Muchardt C, Yaniv M, Hankinson O. 2004. Roles of brahma and brahma/SWI2-related gene 1 in hypoxic induction of the erythropoietin gene. *Journal of Biological Chemistry* **279**:46733–46741. DOI: <https://doi.org/10.1074/jbc.M409002200>, PMID: 15347669
- Weidemann A, Johnson RS. 2009. Nonrenal regulation of EPO synthesis. *Kidney International* **75**:682–688. DOI: <https://doi.org/10.1038/ki.2008.687>, PMID: 19165176
- Yan HB, Wang XF, Zhang Q, Tang ZQ, Jiang YH, Fan HZ, Sun YH, Yang PY, Liu F. 2014. Reduced expression of the chromatin remodeling gene ARID1A enhances gastric Cancer cell migration and invasion via downregulation of E-cadherin transcription. *Carcinogenesis* **35**:867–876. DOI: <https://doi.org/10.1093/carcin/bgt398>, PMID: 24293408
- Zaret KS. 2016. From endoderm to liver bud: paradigms of cell type specification and tissue morphogenesis. *Current Topics in Developmental Biology* **117**:647–669. DOI: <https://doi.org/10.1016/bs.ctdb.2015.12.015>, PMID: 26970006
- Zhai Y, Kuick R, Tipton C, Wu R, Sessine M, Wang Z, Baker SJ, Fearon ER, Cho KR. 2016. Arid1a inactivation in an apc- and Pten-defective mouse ovarian Cancer model enhances epithelial differentiation and prolongs survival. *The Journal of Pathology* **238**:21–30. DOI: <https://doi.org/10.1002/path.4599>, PMID: 26279473